{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T06:22:59Z","timestamp":1794378179033,"version":"4.9.0"},"reference-count":414,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T00:00:00Z","timestamp":1595548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T00:00:00Z","timestamp":1595548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1038\/s41571-020-0403-1","type":"journal-article","created":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T06:04:09Z","timestamp":1595570649000},"page":"9-34","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":945,"title":["TGF\u03b2 biology in cancer progression and immunotherapy"],"prefix":"10.1038","volume":"18","author":[{"given":"Rik","family":"Derynck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon J.","family":"Turley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4474-9668","authenticated-orcid":false,"given":"Rosemary J.","family":"Akhurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,24]]},"reference":[{"key":"403_CR1","doi-asserted-by":"crossref","first-page":"a021865","DOI":"10.1101\/cshperspect.a021865","volume":"8","author":"HL Moses","year":"2016","unstructured":"Moses, H. L., Roberts, A. B. & Derynck, R. The discovery and early days of TGF-\u03b2: a historical perspective. Cold Spring Harb. Perspect. Biol. 8, a021865 (2016).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"403_CR2","first-page":"2842","volume":"41","author":"HL Moses","year":"1981","unstructured":"Moses, H. L., Branum, E. L., Proper, J. A. & Robinson, R. A. Transforming growth factor production by chemically transformed cells. Cancer Res. 41, 2842\u20132848 (1981).","journal-title":"Cancer Res."},{"key":"403_CR3","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.1073\/pnas.78.9.5339","volume":"78","author":"AB Roberts","year":"1981","unstructured":"Roberts, A. B., Anzano, M. A., Lamb, L. C., Smith, J. M. & Sporn, M. B. New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues. Proc. Natl Acad. Sci. USA 78, 5339\u20135343 (1981).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"403_CR4","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/316701a0","volume":"316","author":"R Derynck","year":"1985","unstructured":"Derynck, R. et al. Human transforming growth factor-\u03b2 complementary DNA sequence and expression in normal and transformed cells. Nature 316, 701\u2013705 (1985).","journal-title":"Nature"},{"key":"403_CR5","first-page":"707","volume":"47","author":"R Derynck","year":"1987","unstructured":"Derynck, R. et al. Synthesis of messenger RNAs for transforming growth factors \u03b1 and \u03b2 and the epidermal growth factor receptor by human tumors. Cancer Res. 47, 707\u2013712 (1987).","journal-title":"Cancer Res."},{"key":"403_CR6","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1126\/science.6093254","volume":"226","author":"RF Tucker","year":"1984","unstructured":"Tucker, R. F., Shipley, G. D., Moses, H. L. & Holley, R. W. Growth inhibitor from BSC-1 cells closely related to platelet type beta transforming growth factor. Science 226, 705\u2013707 (1984).","journal-title":"Science"},{"key":"403_CR7","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/nrc1208","volume":"3","author":"PM Siegel","year":"2003","unstructured":"Siegel, P. M. & Massagu\u00e9, J. Cytostatic and apoptotic actions of TGF-\u03b2 in homeostasis and cancer. Nat. Rev. Cancer 3, 807\u2013821 (2003).","journal-title":"Nat. Rev. Cancer"},{"key":"403_CR8","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1083\/jcb.127.6.2021","volume":"127","author":"PJ Miettinen","year":"1994","unstructured":"Miettinen, P. J., Ebner, R., Lopez, A. R. & Derynck, R. TGF-beta-induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J. Cell Biol. 127, 2021\u20132036 (1994).","journal-title":"J. Cell Biol."},{"key":"403_CR9","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/CCO.0b013e32835b6371","volume":"25","author":"Y Katsuno","year":"2013","unstructured":"Katsuno, Y., Lamouille, S. & Derynck, R. TGF-\u03b2 signaling and epithelial-mesenchymal transition in cancer progression. Curr. Opin. Oncol. 25, 76\u201384 (2013).","journal-title":"Curr. Opin. Oncol."},{"key":"403_CR10","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrc3245","volume":"12","author":"WH Fridman","year":"2012","unstructured":"Fridman, W. H., Pages, F., Sautes-Fridman, C. & Galon, J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12, 298\u2013306 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"403_CR11","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nrclinonc.2017.101","volume":"14","author":"WH Fridman","year":"2017","unstructured":"Fridman, W. H., Zitvogel, L., Sautes-Fridman, C. & Kroemer, G. The immune contexture in cancer prognosis and treatment. Nat. Rev. Clin. Oncol. 14, 717\u2013734 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"403_CR12","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nri3902","volume":"15","author":"SJ Turley","year":"2015","unstructured":"Turley, S. J., Cremasco, V. & Astarita, J. L. Immunological hallmarks of stromal cells in the tumour microenvironment. Nat. Rev. Immunol. 15, 669\u2013682 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"403_CR13","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/bs.acr.2015.05.001","volume":"128","author":"JD Peske","year":"2015","unstructured":"Peske, J. D., Woods, A. B. & Engelhard, V. H. Control of CD8 T-cell infiltration into tumors by vasculature and microenvironment. Adv. Cancer Res. 128, 263\u2013307 (2015).","journal-title":"Adv. Cancer Res."},{"key":"403_CR14","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cimid.2018.12.006","volume":"63","author":"A Nicolas-Boluda","year":"2019","unstructured":"Nicolas-Boluda, A. & Donnadieu, E. Obstacles to T cell migration in the tumor microenvironment. Comp. Immunol. Microbiol. Infect. Dis. 63, 22\u201330 (2019).","journal-title":"Comp. Immunol. Microbiol. Infect. Dis."},{"key":"403_CR15","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nri.2015.16","volume":"16","author":"MF Krummel","year":"2016","unstructured":"Krummel, M. F., Bartumeus, F. & Gerard, A. T cell migration, search strategies and mechanisms. Nat. Rev. Immunol. 16, 193\u2013201 (2016).","journal-title":"Nat. Rev. Immunol."},{"key":"403_CR16","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1126\/science.aaa6204","volume":"348","author":"JA Joyce","year":"2015","unstructured":"Joyce, J. A. & Fearon, D. T. T cell exclusion, immune privilege, and the tumor microenvironment. Science 348, 74\u201380 (2015).","journal-title":"Science"},{"key":"403_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen, D. S. & Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1\u201310 (2013).","journal-title":"Immunity"},{"key":"403_CR18","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/nrc3186","volume":"12","author":"MA Swartz","year":"2012","unstructured":"Swartz, M. A. & Lund, A. W. Lymphatic and interstitial flow in the tumour microenvironment: linking mechanobiology with immunity. Nat. Rev. Cancer 12, 210\u2013219 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"403_CR19","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1172\/JCI71603","volume":"124","author":"W Zheng","year":"2014","unstructured":"Zheng, W., Aspelund, A. & Alitalo, K. Lymphangiogenic factors, mechanisms, and applications. J. Clin. Invest. 124, 878\u2013887 (2014).","journal-title":"J. Clin. Invest."},{"key":"403_CR20","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.trecan.2018.03.004","volume":"4","author":"E Lengyel","year":"2018","unstructured":"Lengyel, E., Makowski, L., DiGiovanni, J. & Kolonin, M. G. Cancer as a matter of fat: the crosstalk between adipose tissue and tumors. Trends Cancer 4, 374\u2013384 (2018).","journal-title":"Trends Cancer"},{"key":"403_CR21","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan, S. et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544\u2013548 (2018).","journal-title":"Nature"},{"key":"403_CR22","volume":"9","author":"A Chakravarthy","year":"2018","unstructured":"Chakravarthy, A., Khan, L., Bensler, N. P., Bose, P. & De Carvalho, D. D. TGF-\u03b2-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure. Nat. Commun. 9, 4692 (2018).","journal-title":"Nat. Commun."},{"key":"403_CR23","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature25492","volume":"554","author":"DVF Tauriello","year":"2018","unstructured":"Tauriello, D. V. F. et al. TGF\u03b2 drives immune evasion in genetically reconstituted colon cancer metastasis. Nature 554, 538\u2013543 (2018).","journal-title":"Nature"},{"key":"403_CR24","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","volume":"48","author":"V Thorsson","year":"2018","unstructured":"Thorsson, V. et al. The immune landscape of cancer. Immunity 48, 812\u2013830 (2018).","journal-title":"Immunity"},{"key":"403_CR25","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3390\/cancers10060194","volume":"10","author":"A Dahmani","year":"2018","unstructured":"Dahmani, A. & Delisle, J. S. TGF-\u03b2 in T cell biology: implications for cancer immunotherapy. Cancers 10, 194 (2018).","journal-title":"Cancers"},{"key":"403_CR26","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1080\/14728222.2019.1636034","volume":"23","author":"H Ungefroren","year":"2019","unstructured":"Ungefroren, H. Blockade of TGF-\u03b2 signaling: a potential target for cancer immunotherapy? Expert Opin. Ther. Targets 23, 679\u2013693 (2019).","journal-title":"Expert Opin. Ther. Targets"},{"key":"403_CR27","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","volume":"50","author":"E Batlle","year":"2019","unstructured":"Batlle, E. & Massagu\u00e9, J. Transforming growth factor-\u03b2 signaling in immunity and cancer. Immunity 50, 924\u2013940 (2019).","journal-title":"Immunity"},{"key":"403_CR28","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1126\/science.2163544","volume":"248","author":"MH Sieweke","year":"1990","unstructured":"Sieweke, M. H., Thompson, N. L., Sporn, M. B. & Bissell, M. J. Mediation of wound-related Rous sarcoma virus tumorigenesis by TGF-\u03b2. Science 248, 1656\u20131660 (1990).","journal-title":"Science"},{"key":"403_CR29","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/331363a0","volume":"331","author":"RJ Akhurst","year":"1988","unstructured":"Akhurst, R. J., Fee, F. & Balmain, A. Localized production of TGF-\u03b2 mRNA in tumour promoter-stimulated mouse epidermis. Nature 331, 363\u2013365 (1988).","journal-title":"Nature"},{"key":"403_CR30","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0304-3835(81)90150-6","volume":"14","author":"JA DiPaolo","year":"1981","unstructured":"DiPaolo, J. A., DeMarinis, A. J., Evans, C. H. & Doniger, J. Expression of initiated and promoted stages of irradiation carcinogenesis in vitro. Cancer Lett. 14, 243\u2013249 (1981).","journal-title":"Cancer Lett."},{"key":"403_CR31","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.3389\/fimmu.2019.01078","volume":"10","author":"H Harjunpaa","year":"2019","unstructured":"Harjunpaa, H., Llort Asens, M., Guenther, C. & Fagerholm, S. C. Cell adhesion molecules and their roles and regulation in the immune and tumor microenvironment. Front. Immunol. 10, 1078 (2019).","journal-title":"Front. Immunol."},{"key":"403_CR32","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3389\/fcell.2019.00110","volume":"7","author":"A Onnis","year":"2019","unstructured":"Onnis, A. & Baldari, C. T. Orchestration of immunological synapse assembly by vesicular trafficking. Front. Cell Dev. 7, 110 (2019).","journal-title":"Front. Cell Dev."},{"key":"403_CR33","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.3389\/fimmu.2019.01447","volume":"10","author":"P Castro-Sanchez","year":"2019","unstructured":"Castro-Sanchez, P., Aguilar-Sopena, O., Alegre-Gomez, S., Ramirez-Munoz, R. & Roda-Navarro, P. Regulation of CD4+ T cell signaling and immunological synapse by protein tyrosine phosphatases: molecular mechanisms in autoimmunity. Front. Immunol. 10, 1447 (2019).","journal-title":"Front. Immunol."},{"key":"403_CR34","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrclinonc.2017.44","volume":"14","author":"T Shibue","year":"2017","unstructured":"Shibue, T. & Weinberg, R. A. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat. Rev. Clin. Oncol. 14, 611\u2013629 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"403_CR35","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nrc.2017.118","volume":"18","author":"T Brabletz","year":"2018","unstructured":"Brabletz, T., Kalluri, R., Nieto, M. A. & Weinberg, R. A. EMT in cancer. Nat. Rev. Cancer 18, 128\u2013134 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"403_CR36","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cell.2016.06.028","volume":"166","author":"MA Nieto","year":"2016","unstructured":"Nieto, M. A., Huang, R. Y., Jackson, R. A. & Thiery, J. P. EMT: 2016. Cell 166, 21\u201345 (2016).","journal-title":"Cell"},{"key":"403_CR37","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41580-018-0080-4","volume":"20","author":"A Dongre","year":"2019","unstructured":"Dongre, A. & Weinberg, R. A. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat. Rev. Mol. Cell. Biol. 20, 69\u201384 (2019).","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"403_CR38","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1158\/2326-6066.CIR-18-0086","volume":"6","author":"F Zhao","year":"2018","unstructured":"Zhao, F. et al. Stromal fibroblasts mediate anti-PD-1 resistance via MMP-9 and dictate TGF\u03b2 inhibitor sequencing in melanoma. Cancer Immunol. Res. 6, 1459\u20131471 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"403_CR39","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1084\/jem.20140692","volume":"211","author":"D Ohlund","year":"2014","unstructured":"Ohlund, D., Elyada, E. & Tuveson, D. Fibroblast heterogeneity in the cancer wound. J. Exp. Med. 211, 1503\u20131523 (2014).","journal-title":"J. Exp. Med."},{"key":"403_CR40","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nrc.2016.73","volume":"16","author":"R Kalluri","year":"2016","unstructured":"Kalluri, R. The biology and function of fibroblasts in cancer. Nat. Rev. Cancer 16, 582\u2013598 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"403_CR41","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0092-8674(00)80127-0","volume":"86","author":"W Cui","year":"1996","unstructured":"Cui, W. et al. TGF\u03b21 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 86, 531\u2013542 (1996).","journal-title":"Cell"},{"key":"403_CR42","first-page":"393","volume":"9","author":"G Portella","year":"1998","unstructured":"Portella, G. et al. Transforming growth factor beta is essential for spindle cell conversion of mouse skin carcinoma in vivo: implications for tumor invasion. Cell Growth Differ. 9, 393\u2013404 (1998).","journal-title":"Cell Growth Differ."},{"key":"403_CR43","doi-asserted-by":"crossref","first-page":"a021907","DOI":"10.1101\/cshperspect.a021907","volume":"8","author":"IB Robertson","year":"2016","unstructured":"Robertson, I. B. & Rifkin, D. B. Regulation of the bioavailability of TGF-\u03b2 and TGF-\u03b2-related proteins. Cold Spring Harb. Perspect. Biol. 8, a021907 (2016).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"403_CR44","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197108122850711","volume":"285","author":"J Folkman","year":"1971","unstructured":"Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182\u20131186 (1971).","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 3)","key":"403_CR45","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000088479","volume":"69","author":"N Ferrara","year":"2005","unstructured":"Ferrara, N. VEGF as a therapeutic target in cancer. Oncology 69 (Suppl. 3)), 11\u201316 (2005).","journal-title":"Oncology"},{"key":"403_CR46","doi-asserted-by":"crossref","first-page":"a006486","DOI":"10.1101\/cshperspect.a006486","volume":"2","author":"S Goel","year":"2012","unstructured":"Goel, S., Wong, A. H. & Jain, R. K. Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. Cold Spring Harb. Perspect. Med. 2, a006486 (2012).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"403_CR47","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.it.2018.08.001","volume":"39","author":"A Johansson-Percival","year":"2018","unstructured":"Johansson-Percival, A., He, B. & Ganss, R. Immunomodulation of tumor vessels: it takes two to tango. Trends Immunol. 39, 801\u2013814 (2018).","journal-title":"Trends Immunol."},{"key":"403_CR48","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1146\/annurev-med-012017-043208","volume":"69","author":"M Hashimoto","year":"2018","unstructured":"Hashimoto, M. et al. CD8 T cell exhaustion in chronic infection and cancer: opportunities for interventions. Annu. Rev. Med. 69, 301\u2013318 (2018).","journal-title":"Annu. Rev. Med."},{"key":"403_CR49","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41577-018-0061-z","volume":"18","author":"L Chiossone","year":"2018","unstructured":"Chiossone, L., Dumas, P. Y., Vienne, M. & Vivier, E. Natural killer cells and other innate lymphoid cells in cancer. Nat. Rev. Immunol. 18, 671\u2013688 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"403_CR50","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.3389\/fimmu.2018.03059","volume":"9","author":"C Fu","year":"2018","unstructured":"Fu, C. & Jiang, A. Dendritic cells and CD8 T cell immunity in tumor microenvironment. Front. Immunol. 9, 3059 (2018).","journal-title":"Front. Immunol."},{"key":"403_CR51","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1126\/science.1164206","volume":"322","author":"K Hildner","year":"2008","unstructured":"Hildner, K. et al. Batf3 deficiency reveals a critical role for CD8\u03b2+ dendritic cells in cytotoxic T cell immunity. Science 322, 1097\u20131100 (2008).","journal-title":"Science"},{"key":"403_CR52","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","volume":"20","author":"SK Wculek","year":"2020","unstructured":"Wculek, S. K. et al. Dendritic cells in cancer immunology and immunotherapy. Nat. Rev. Immunol. 20, 7\u201324 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"403_CR53","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ccr.2012.01.008","volume":"21","author":"JJ Engelhardt","year":"2012","unstructured":"Engelhardt, J. J. et al. Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells. Cancer Cell 21, 402\u2013417 (2012).","journal-title":"Cancer Cell"},{"key":"403_CR54","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2016.03.012","volume":"44","author":"H Salmon","year":"2016","unstructured":"Salmon, H. et al. Expansion and activation of CD103+ dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity 44, 924\u2013938 (2016).","journal-title":"Immunity"},{"key":"403_CR55","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrc.2016.54","volume":"16","author":"C Engblom","year":"2016","unstructured":"Engblom, C., Pfirschke, C. & Pittet, M. J. The role of myeloid cells in cancer therapies. Nat. Rev. Cancer 16, 447\u2013462 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"403_CR56","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/nature24302","volume":"551","author":"S Shalapour","year":"2017","unstructured":"Shalapour, S. et al. Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity. Nature 551, 340\u2013345 (2017).","journal-title":"Nature"},{"key":"403_CR57","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1002\/ijc.27572","volume":"131","author":"Z Li","year":"2012","unstructured":"Li, Z. et al. Gr-1+CD11b+ cells are responsible for tumor promoting effect of TGF-\u03b2 in breast cancer progression. Int. J. Cancer 131, 2584\u20132595 (2012).","journal-title":"Int. J. Cancer"},{"key":"403_CR58","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1073\/pnas.0408197102","volume":"102","author":"ML Chen","year":"2005","unstructured":"Chen, M. L. et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-\u03b2 signals in vivo. Proc. Natl Acad. Sci. USA 102, 419\u2013424 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"403_CR59","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1084\/jem.20042276","volume":"201","author":"JC Marie","year":"2005","unstructured":"Marie, J. C., Letterio, J. J., Gavin, M. & Rudensky, A. Y. TGF-\u03b21 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J. Exp. Med. 201, 1061\u20131067 (2005).","journal-title":"J. Exp. Med."},{"key":"403_CR60","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/ni1549","volume":"9","author":"Y Tone","year":"2008","unstructured":"Tone, Y. et al. Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. Nat. Immunol. 9, 194\u2013202 (2008).","journal-title":"Nat. Immunol."},{"key":"403_CR61","doi-asserted-by":"crossref","first-page":"a022236","DOI":"10.1101\/cshperspect.a022236","volume":"9","author":"S Sanjabi","year":"2017","unstructured":"Sanjabi, S., Oh, S. A. & Li, M. O. Regulation of the immune response by TGF-\u03b2: from conception to autoimmunity and infection. Cold Spring Harb. Perspect. Biol. 9, a022236 (2017).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"403_CR62","volume":"40","author":"M Liu","year":"2018","unstructured":"Liu, M., Li, S. & Li, M. O. TGF-\u03b2 control of adaptive immune tolerance: a break from Treg cells. Bioessays 40, e1800063 (2018).","journal-title":"Bioessays"},{"key":"403_CR63","doi-asserted-by":"crossref","first-page":"162","DOI":"10.4161\/onci.1.2.18481","volume":"1","author":"MK Donkor","year":"2012","unstructured":"Donkor, M. K., Sarkar, A. & Li, M. O. TGF-\u03b21 produced by activated CD4+ T cells antagonizes T cell surveillance of tumor development. Oncoimmunology 1, 162\u2013171 (2012).","journal-title":"Oncoimmunology"},{"key":"403_CR64","doi-asserted-by":"crossref","first-page":"284ra256","DOI":"10.1126\/scitranslmed.aaa1983","volume":"7","author":"J Cuende","year":"2015","unstructured":"Cuende, J. et al. Monoclonal antibodies against GARP\/TGF-\u03b21 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo. Sci. Transl Med. 7, 284ra256 (2015).","journal-title":"Sci. Transl Med."},{"key":"403_CR65","doi-asserted-by":"crossref","first-page":"aav5183","DOI":"10.1126\/scisignal.aav5183","volume":"12","author":"R Derynck","year":"2019","unstructured":"Derynck, R. & Budi, E. H. Specificity, versatility, and control of TGF-\u03b2 family signaling. Sci. Signal. 12, aav5183 (2019).","journal-title":"Sci. Signal."},{"key":"403_CR66","doi-asserted-by":"crossref","first-page":"7155","DOI":"10.1016\/S0021-9258(18)32345-7","volume":"258","author":"RK Assoian","year":"1983","unstructured":"Assoian, R. K., Komoriya, A., Meyers, C. A., Miller, D. M. & Sporn, M. B. Transforming growth factor-\u03b2 in human platelets. Identification of a major storage site, purification, and characterization. J. Biol. Chem. 258, 7155\u20137160 (1983).","journal-title":"J. Biol. Chem."},{"key":"403_CR67","doi-asserted-by":"crossref","first-page":"10783","DOI":"10.1016\/S0021-9258(18)38039-6","volume":"263","author":"S Cheifetz","year":"1988","unstructured":"Cheifetz, S. et al. Heterodimeric transforming growth factor \u03b2. Biological properties and interaction with three types of cell surface receptors. J. Biol. Chem. 263, 10783\u201310789 (1988).","journal-title":"J. Biol. Chem."},{"key":"403_CR68","first-page":"5831","volume":"54","author":"W Cui","year":"1994","unstructured":"Cui, W., Kemp, C. J., Duffie, E., Balmain, A. & Akhurst, R. J. Lack of transforming growth factor-\u03b21 expression in benign skin tumors of p53null mice is prognostic for a high risk of malignant conversion. Cancer Res. 54, 5831\u20135836 (1994).","journal-title":"Cancer Res."},{"key":"403_CR69","volume":"6","author":"X Qin","year":"2016","unstructured":"Qin, X. et al. TGF\u03b23-mediated induction of periostin facilitates head and neck cancer growth and is associated with metastasis. Sci. Rep. 6, 20587 (2016).","journal-title":"Sci. Rep."},{"key":"403_CR70","doi-asserted-by":"crossref","first-page":"101042831774825","DOI":"10.1177\/1010428317748254","volume":"40","author":"MY Hachim","year":"2018","unstructured":"Hachim, M. Y., Hachim, I. Y., Dai, M., Ali, S. & Lebrun, J. J. Differential expression of TGF\u03b2 isoforms in breast cancer highlights different roles during breast cancer progression. Tumor Biol. 40, 1010428317748254 (2018).","journal-title":"Tumor Biol."},{"key":"403_CR71","doi-asserted-by":"crossref","first-page":"eaay8456","DOI":"10.1126\/scitranslmed.aay8456","volume":"12","author":"CJ Martin","year":"2020","unstructured":"Martin, C. J. et al. Selective inhibition of TGF\u03b21 activation overcomes primary resistance to checkpoint blockade therapy by altering tumour immune landscape. Sci. Transl Med. 12, eaay8456 (2020).","journal-title":"Sci. Transl Med."},{"key":"403_CR72","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1039\/C7MB00251C","volume":"13","author":"J Stockis","year":"2017","unstructured":"Stockis, J., Dedobbeleer, O. & Lucas, S. Role of GARP in the activation of latent TGF-\u03b21. Mol. Biosyst. 13, 1925\u20131935 (2017).","journal-title":"Mol. Biosyst."},{"key":"403_CR73","doi-asserted-by":"crossref","first-page":"eaay4860","DOI":"10.1126\/scitranslmed.aay4860","volume":"12","author":"A Metelli","year":"2020","unstructured":"Metelli, A. et al. Thrombin contributes to cancer immune evasion via proteolysis of platelet-bound GARP to activate LTGF-\u03b2. Sci. Transl Med. 12, eaay4860 (2020).","journal-title":"Sci. Transl Med."},{"key":"403_CR74","first-page":"545","volume":"40","author":"R Roubin","year":"1996","unstructured":"Roubin, R. et al. Structure and developmental expression of mouse Garp, a gene encoding a new leucine-rich repeat-containing protein. Int. J. Dev. Biol. 40, 545\u2013555 (1996).","journal-title":"Int. J. Dev. Biol."},{"key":"403_CR75","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.cell.2018.05.027","volume":"174","author":"Y Qin","year":"2018","unstructured":"Qin, Y. et al. A milieu molecule for TGF-\u03b2 required for microglia function in the nervous system. Cell 174, 156\u2013171 (2018).","journal-title":"Cell"},{"key":"403_CR76","volume":"14","author":"W Ma","year":"2019","unstructured":"Ma, W., Qin, Y., Chapuy, B. & Lu, C. LRRC33 is a novel binding and potential regulating protein of TGF-\u03b21 function in human acute myeloid leukemia cells. PLoS ONE 14, e0213482 (2019).","journal-title":"PLoS ONE"},{"key":"403_CR77","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1158\/2159-8290.CD-19-0644","volume":"10","author":"CX Dominguez","year":"2020","unstructured":"Dominguez, C. X. et al. Single-cell RNA sequencing reveals stromal evolution into LRRC15+ myofibroblasts as a determinant of patient response to cancer immunotherapy. Cancer Discov. 10, 232\u2013253 (2020).","journal-title":"Cancer Discov."},{"key":"403_CR78","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1158\/0008-5472.CAN-18-0327","volume":"78","author":"JW Purcell","year":"2018","unstructured":"Purcell, J. W. et al. LRRC15 is a novel mesenchymal protein and stromal target for antibody-drug conjugates. Cancer Res. 78, 4059\u20134072 (2018).","journal-title":"Cancer Res."},{"key":"403_CR79","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature10152","volume":"474","author":"M Shi","year":"2011","unstructured":"Shi, M. et al. Latent TGF-\u03b2 structure and activation. Nature 474, 343\u2013349 (2011).","journal-title":"Nature"},{"key":"403_CR80","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.bbadis.2012.10.005","volume":"1832","author":"NC Henderson","year":"2013","unstructured":"Henderson, N. C. & Sheppard, D. Integrin-mediated regulation of TGF\u03b2 in fibrosis. Biochim. Biophys. Acta. 1832, 891\u2013896 (2013).","journal-title":"Biochim. Biophys. Acta."},{"key":"403_CR81","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.3390\/cancers11091221","volume":"11","author":"NF Brown","year":"2019","unstructured":"Brown, N. F. & Marshall, J. F. Integrin-mediated TGF\u03b2 activation modulates the tumour microenvironment. Cancers 11, 1221 (2019).","journal-title":"Cancers"},{"key":"403_CR82","doi-asserted-by":"crossref","first-page":"E10161","DOI":"10.1073\/pnas.1710680114","volume":"114","author":"J Stockis","year":"2017","unstructured":"Stockis, J. et al. Blocking immunosuppression by human Tregs in vivo with antibodies targeting integrin \u03b1v\u03b28. Proc. Natl Acad. Sci. USA 114, E10161\u2013E10168 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"403_CR83","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1523\/JNEUROSCI.5648-11.2012","volume":"32","author":"TD Arnold","year":"2012","unstructured":"Arnold, T. D. et al. Defective retinal vascular endothelial cell development as a consequence of impaired integrin \u03b1v\u03b28-mediated activation of transforming growth factor-\u03b2. J. Neurosci. 32, 1197\u20131206 (2012).","journal-title":"J. Neurosci."},{"key":"403_CR84","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1242\/dev.107193","volume":"141","author":"TD Arnold","year":"2014","unstructured":"Arnold, T. D. et al. Excessive vascular sprouting underlies cerebral hemorrhage in mice lacking \u03b1V\u03b28-TGF\u03b2 signaling in the brain. Development 141, 4489\u20134499 (2014).","journal-title":"Development"},{"key":"403_CR85","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.122591","volume":"3","author":"N Takasaka","year":"2018","unstructured":"Takasaka, N. et al. Integrin \u03b1v\u03b28-expressing tumor cells evade host immunity by regulating TGF-\u03b2 activation in immune cells. JCI Insight 3, e122591 (2018).","journal-title":"JCI Insight"},{"key":"403_CR86","doi-asserted-by":"crossref","first-page":"a022061","DOI":"10.1101\/cshperspect.a022061","volume":"8","author":"A Hata","year":"2016","unstructured":"Hata, A. & Chen, Y. G. TGF-\u03b2 signaling from receptors to Smads. Cold Spring Harb. Perspect. Biol. 8, a022061 (2016).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"403_CR87","doi-asserted-by":"crossref","first-page":"a022079","DOI":"10.1101\/cshperspect.a022079","volume":"8","author":"CS Hill","year":"2016","unstructured":"Hill, C. S. Transcriptional control by the SMADs. Cold Spring Harb. Perspect. Biol. 8, a022079 (2016).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"403_CR88","doi-asserted-by":"crossref","first-page":"a022053","DOI":"10.1101\/cshperspect.a022053","volume":"8","author":"CH Heldin","year":"2016","unstructured":"Heldin, C. H. & Moustakas, A. Signaling receptors for TGF-\u03b2 family members. Cold Spring Harb. Perspect. Biol. 8, a022053 (2016).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"403_CR89","doi-asserted-by":"crossref","first-page":"a022129","DOI":"10.1101\/cshperspect.a022129","volume":"9","author":"YE Zhang","year":"2017","unstructured":"Zhang, Y. E. Non-Smad signaling pathways of the TGF-\u03b2 family. Cold Spring Harb. Perspect. Biol. 9, a022129 (2017).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"403_CR90","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","volume":"141","author":"MA Lemmon","year":"2010","unstructured":"Lemmon, M. A. & Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 141, 1117\u20131134 (2010).","journal-title":"Cell"},{"key":"403_CR91","first-page":"ra96","volume":"8","author":"EH Budi","year":"2015","unstructured":"Budi, E. H., Muthusamy, B. P. & Derynck, R. The insulin response integrates increased TGF-\u03b2 signaling through Akt-induced enhancement of cell surface delivery of TGF-\u03b2 receptors. Sci. Signal. 8, ra96 (2015).","journal-title":"Sci. Signal."},{"key":"403_CR92","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.devcel.2009.05.010","volume":"17","author":"L Wu","year":"2009","unstructured":"Wu, L. & Derynck, R. Essential role of TGF-\u03b2 signaling in glucose-induced cell hypertrophy. Dev. Cell 17, 35\u201348 (2009).","journal-title":"Dev. Cell"},{"key":"403_CR93","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s13238-014-0058-8","volume":"5","author":"J Zhang","year":"2014","unstructured":"Zhang, J. et al. The regulation of TGF-\u03b2\/SMAD signaling by protein deubiquitination. Protein. Cell 5, 503\u2013517 (2014).","journal-title":"Protein. Cell"},{"key":"403_CR94","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.molcel.2009.06.018","volume":"35","author":"C Liu","year":"2009","unstructured":"Liu, C., Xu, P., Lamouille, S., Xu, J. & Derynck, R. TACE-mediated ectodomain shedding of the type I TGF-\u03b2 receptor downregulates TGF-\u03b2 signaling. Mol. Cell 35, 26\u201336 (2009).","journal-title":"Mol. Cell"},{"key":"403_CR95","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/ncb807","volume":"4","author":"M Oft","year":"2002","unstructured":"Oft, M., Akhurst, R. J. & Balmain, A. Metastasis is driven by sequential elevation of H-Ras and Smad2 levels. Nat. Cell Biol. 4, 487\u2013494 (2002).","journal-title":"Nat. Cell Biol."},{"key":"403_CR96","first-page":"4978","volume":"10","author":"MC Birchenall-Roberts","year":"1990","unstructured":"Birchenall-Roberts, M. C. et al. Transcriptional regulation of the transforming growth factor \u03b21 promoter by v-src gene products is mediated through the AP-1 complex. Mol. Cell Biol. 10, 4978\u20134983 (1990).","journal-title":"Mol. Cell Biol."},{"key":"403_CR97","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1038\/sj.onc.1201129","volume":"14","author":"P Thatikunta","year":"1997","unstructured":"Thatikunta, P., Raj, G. V., Kundu, M., Khalili, K. & Amini, S. The transcription factor E2F-1 modulates TGF-\u03b21 RNA expression in glial cells. Oncogene 14, 2959\u20132969 (1997).","journal-title":"Oncogene"},{"key":"403_CR98","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1101\/gad.9.8.945","volume":"9","author":"W Cui","year":"1995","unstructured":"Cui, W. et al. Concerted action of TGF-\u03b21 and its type II receptor in control of epidermal homeostasis in transgenic mice. Genes Dev. 9, 945\u2013955 (1995).","journal-title":"Genes Dev."},{"key":"403_CR99","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1146\/annurev-med-062913-051343","volume":"67","author":"IA Mayer","year":"2016","unstructured":"Mayer, I. A. & Arteaga, C. L. The PI3K\/AKT pathway as a target for cancer treatment. Annu. Rev. Med. 67, 11\u201328 (2016).","journal-title":"Annu. Rev. Med."},{"key":"403_CR100","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.cell.2017.04.001","volume":"169","author":"BD Manning","year":"2017","unstructured":"Manning, B. D. & Toker, A. AKT\/PKB signaling: navigating the network. Cell 169, 381\u2013405 (2017).","journal-title":"Cell"},{"key":"403_CR101","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s13277-015-4374-2","volume":"37","author":"L Guo","year":"2016","unstructured":"Guo, L. et al. MicroRNAs, TGF-\u03b2 signaling, and the inflammatory microenvironment in cancer. Tumor Biol. 37, 115\u2013125 (2016).","journal-title":"Tumor Biol."},{"key":"403_CR102","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ceb.2013.01.008","volume":"25","author":"S Lamouille","year":"2013","unstructured":"Lamouille, S., Subramanyam, D., Blelloch, R. & Derynck, R. Regulation of epithelial-mesenchymal and mesenchymal-epithelial transitions by microRNAs. Curr. Opin. Cell Biol. 25, 200\u2013207 (2013).","journal-title":"Curr. Opin. Cell Biol."},{"key":"403_CR103","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ceb.2012.12.005","volume":"25","author":"MT Blahna","year":"2013","unstructured":"Blahna, M. T. & Hata, A. Regulation of miRNA biogenesis as an integrated component of growth factor signaling. Curr. Opin. Cell Biol. 25, 233\u2013240 (2013).","journal-title":"Curr. Opin. Cell Biol."},{"key":"403_CR104","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.1038\/onc.2011.493","volume":"31","author":"K Horiguchi","year":"2012","unstructured":"Horiguchi, K. et al. TGF-\u03b2 drives epithelial-mesenchymal transition through \u03b2EF1-mediated downregulation of ESRP. Oncogene 31, 3190\u20133201 (2012).","journal-title":"Oncogene"},{"key":"403_CR105","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.cyto.2017.12.032","volume":"118","author":"BV Howley","year":"2019","unstructured":"Howley, B. V. & Howe, P. H. TGF-\u03b2 signaling in cancer: post-transcriptional regulation of EMT via hnRNP E1. Cytokine 118, 19\u201326 (2019).","journal-title":"Cytokine"},{"key":"403_CR106","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1126\/science.1176009","volume":"326","author":"RO Hynes","year":"2009","unstructured":"Hynes, R. O. The extracellular matrix: not just pretty fibrils. Science 326, 1216\u20131219 (2009).","journal-title":"Science"},{"key":"403_CR107","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/BOR.0b013e32835b137b","volume":"25","author":"D Hubmacher","year":"2013","unstructured":"Hubmacher, D. & Apte, S. S. The biology of the extracellular matrix: novel insights. Curr. Opin. Rheumatol. 25, 65\u201370 (2013).","journal-title":"Curr. Opin. Rheumatol."},{"key":"403_CR108","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/nrc1456","volume":"4","author":"CH Heldin","year":"2004","unstructured":"Heldin, C. H., Rubin, K., Pietras, K. & Ostman, A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat. Rev. Cancer 4, 806\u2013813 (2004).","journal-title":"Nat. Rev. Cancer"},{"key":"403_CR109","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0092-8674(00)00121-5","volume":"103","author":"J Massagu\u00e9","year":"2000","unstructured":"Massagu\u00e9, J., Blain, S. W. & Lo, R. S. TGF\u03b2 signaling in growth control, cancer, and heritable disorders. Cell 103, 295\u2013309 (2000).","journal-title":"Cell"},{"key":"403_CR110","doi-asserted-by":"crossref","first-page":"a022145","DOI":"10.1101\/cshperspect.a022145","volume":"9","author":"Y Zhang","year":"2017","unstructured":"Zhang, Y., Alexander, P. B. & Wang, X. F. TGF-\u03b2 family signaling in the control of cell proliferation and survival. Cold Spring Harb. Perspect. Biol. 9, a022145 (2017).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"403_CR111","doi-asserted-by":"crossref","first-page":"a022277","DOI":"10.1101\/cshperspect.a022277","volume":"9","author":"J Seoane","year":"2017","unstructured":"Seoane, J. & Gomis, R. R. TGF-\u03b2 family signaling in tumor suppression and cancer progression. Cold Spring Harb. Perspect. Biol. 9, a022277 (2017).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"403_CR112","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrc2853","volume":"10","author":"H Ikushima","year":"2010","unstructured":"Ikushima, H. & Miyazono, K. TGF\u03b2 signalling: a complex web in cancer progression. Nat. Rev. Cancer 10, 415\u2013424 (2010).","journal-title":"Nat. Rev. Cancer"},{"key":"403_CR113","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1053\/j.gastro.2009.12.010","volume":"138","author":"MS Pino","year":"2010","unstructured":"Pino, M. S. et al. Epithelial to mesenchymal transition is impaired in colon cancer cells with microsatellite instability. Gastroenterology 138, 1406\u20131417 (2010).","journal-title":"Gastroenterology"},{"key":"403_CR114","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/nature14129","volume":"517","author":"Cancer Genome Atlas Network.","year":"2015","unstructured":"Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517, 576\u2013582 (2015).","journal-title":"Nature"},{"key":"403_CR115","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1053\/j.gastro.2017.05.012","volume":"153","author":"SY Cho","year":"2017","unstructured":"Cho, S. Y. et al. Sporadic early-onset diffuse gastric cancers have high frequency of somatic CDH1 alterations, but low frequency of somatic RHOA mutations compared with late-onset cancers. Gastroenterology 153, 536\u2013549.e26 (2017).","journal-title":"Gastroenterology"},{"key":"403_CR116","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.cels.2018.08.010","volume":"7","author":"A Korkut","year":"2018","unstructured":"Korkut, A. et al. A pan-cancer analysis reveals high-frequency genetic alterations in mediators of signaling by the TGF-\u03b2 superfamily. Cell Syst. 7, 422\u2013437.e7 (2018).","journal-title":"Cell Syst."},{"key":"403_CR117","doi-asserted-by":"crossref","first-page":"4674","DOI":"10.1158\/1078-0432.CCR-09-0227","volume":"15","author":"A Blackford","year":"2009","unstructured":"Blackford, A. et al. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin. Cancer Res. 15, 4674\u20134679 (2009).","journal-title":"Clin. Cancer Res."},{"key":"403_CR118","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1073\/pnas.0712044105","volume":"105","author":"P Descargues","year":"2008","unstructured":"Descargues, P. et al. IKK\u03b2 is a critical coregulator of a Smad4-independent TGF\u03b2-Smad2\/3 signaling pathway that controls keratinocyte differentiation. Proc. Natl Acad. Sci. USA 105, 2487\u20132492 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"403_CR119","doi-asserted-by":"crossref","first-page":"8108","DOI":"10.1128\/MCB.25.18.8108-8125.2005","volume":"25","author":"L Levy","year":"2005","unstructured":"Levy, L. & Hill, C. S. Smad4 dependency defines two classes of transforming growth factor \u03b2 target genes and distinguishes TGF-\u03b2-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses. Mol. Cell Biol. 25, 8108\u20138125 (2005).","journal-title":"Mol. Cell Biol."},{"key":"403_CR120","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1038\/cdd.2014.131","volume":"21","author":"L Yang","year":"2014","unstructured":"Yang, L. & Karin, M. Roles of tumor suppressors in regulating tumor-associated inflammation. Cell Death Differ. 21, 1677\u20131686 (2014).","journal-title":"Cell Death Differ."},{"key":"403_CR121","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-06027-1","volume":"9","author":"GJ Inman","year":"2018","unstructured":"Inman, G. J. et al. The genomic landscape of cutaneous SCC reveals drivers and a novel azathioprine-associated mutational signature. Nat. Commun. 9, 3667 (2018).","journal-title":"Nat. Commun."},{"key":"403_CR122","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/onc.2013.527","volume":"34","author":"S Busch","year":"2015","unstructured":"Busch, S. et al. TGF-\u03b2 receptor type-2 expression in cancer-associated fibroblasts regulates breast cancer cell growth and survival and is a prognostic marker in pre-menopausal breast cancer. Oncogene 34, 27\u201338 (2015).","journal-title":"Oncogene"},{"key":"403_CR123","doi-asserted-by":"crossref","first-page":"726","DOI":"10.3390\/cancers11050726","volume":"11","author":"S Suriyamurthy","year":"2019","unstructured":"Suriyamurthy, S., Baker, D., ten Dijke, P. & Iyengar, P. V. Epigenetic reprogramming of TGF-\u03b2 signaling in breast cancer. Cancers 11, 726 (2019).","journal-title":"Cancers"},{"key":"403_CR124","doi-asserted-by":"crossref","first-page":"a022095","DOI":"10.1101\/cshperspect.a022095","volume":"9","author":"K Miyazawa","year":"2017","unstructured":"Miyazawa, K. & Miyazono, K. Regulation of TGF-\u03b2 family signaling by inhibitory Smads. Cold Spring Harb. Perspect. Biol. 9, a022095 (2017).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"403_CR125","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3390\/cancers10060159","volume":"10","author":"J Tang","year":"2018","unstructured":"Tang, J., Gifford, C. C., Samarakoon, R. & Higgins, P. J. Deregulation of negative controls on TGF-\u03b21 signaling in tumor progression. Cancers 10, 159 (2018).","journal-title":"Cancers"},{"key":"403_CR126","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1172\/JCI39675","volume":"119","author":"R Kalluri","year":"2009","unstructured":"Kalluri, R. EMT: when epithelial cells decide to become mesenchymal-like cells. J. Clin. Invest. 119, 1417\u20131419 (2009).","journal-title":"J. Clin. Invest."},{"key":"403_CR127","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.devcel.2019.04.026","volume":"49","author":"R Derynck","year":"2019","unstructured":"Derynck, R. & Weinberg, R. A. EMT and cancer: more than meets the eye. Dev. Cell 49, 313\u2013316 (2019).","journal-title":"Dev. Cell"},{"key":"403_CR128","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nrm3758","volume":"15","author":"S Lamouille","year":"2014","unstructured":"Lamouille, S., Xu, J. & Derynck, R. Molecular mechanisms of epithelial-mesenchymal transition. Nat. Rev. Mol. Cell Biol. 15, 178\u2013196 (2014).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"403_CR129","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.31756","volume":"7","author":"A Ramachandran","year":"2018","unstructured":"Ramachandran, A. et al. TGF-\u03b2 uses a novel mode of receptor activation to phosphorylate SMAD1\/5 and induce epithelial-to-mesenchymal transition. eLife 7, e31756 (2018).","journal-title":"eLife"},{"key":"403_CR130","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1172\/JCI36183","volume":"119","author":"M Zeisberg","year":"2009","unstructured":"Zeisberg, M. & Neilson, E. G. Biomarkers for epithelial-mesenchymal transitions. J. Clin. Invest. 119, 1429\u20131437 (2009).","journal-title":"J. Clin. Invest."},{"key":"403_CR131","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1038\/nm.3336","volume":"19","author":"WL Tam","year":"2013","unstructured":"Tam, W. L. & Weinberg, R. A. The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat. Med. 19, 1438\u20131449 (2013).","journal-title":"Nat. Med."},{"key":"403_CR132","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ceb.2014.09.001","volume":"31","author":"R Derynck","year":"2014","unstructured":"Derynck, R., Muthusamy, B. P. & Saeteurn, K. Y. Signaling pathway cooperation in TGF-\u03b2-induced epithelial-mesenchymal transition. Curr. Opin. Cell Biol. 31, 56\u201366 (2014).","journal-title":"Curr. Opin. Cell Biol."},{"key":"403_CR133","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s10555-016-9648-7","volume":"35","author":"CL Chaffer","year":"2016","unstructured":"Chaffer, C. L., San Juan, B. P., Lim, E. & Weinberg, R. A. EMT, cell plasticity and metastasis. Cancer Metastasis Rev. 35, 645\u2013654 (2016).","journal-title":"Cancer Metastasis Rev."},{"key":"403_CR134","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.tcb.2018.12.001","volume":"29","author":"I Pastushenko","year":"2019","unstructured":"Pastushenko, I. & Blanpain, C. EMT transition states during tumor progression and metastasis. Trends Cell Biol. 29, 212\u2013226 (2019).","journal-title":"Trends Cell Biol."},{"key":"403_CR135","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.pharmthera.2018.09.007","volume":"194","author":"MK Jolly","year":"2019","unstructured":"Jolly, M. K. et al. Hybrid epithelial\/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas. Pharmacol. Ther. 194, 161\u2013184 (2019).","journal-title":"Pharmacol. Ther."},{"key":"403_CR136","doi-asserted-by":"crossref","first-page":"dev172056","DOI":"10.1242\/dev.172056","volume":"146","author":"AK Mishra","year":"2019","unstructured":"Mishra, A. K., Campanale, J. P., Mondo, J. A. & Montell, D. J. Cell interactions in collective cell migration. Development 146, dev172056 (2019).","journal-title":"Development"},{"key":"403_CR137","doi-asserted-by":"publisher","unstructured":"Celia-Terrassa, T. & Jolly, M. K. Cancer stem cells and epithelial-to-mesenchymal transition in cancer metastasis. Cold Spring Harb. Perspect. Med. https:\/\/doi.org\/10.1101\/cshperspect.a036905 (2019).","DOI":"10.1101\/cshperspect.a036905"},{"key":"403_CR138","first-page":"5619472","volume":"2017","author":"PM Aponte","year":"2017","unstructured":"Aponte, P. M. & Caicedo, A. Stemness in cancer: stem cells, cancer stem cells, and their microenvironment. Stem Cell Int. 2017, 5619472 (2017).","journal-title":"Stem Cell Int."},{"key":"403_CR139","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.cell.2011.04.029","volume":"145","author":"C Scheel","year":"2011","unstructured":"Scheel, C. et al. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 145, 926\u2013940 (2011).","journal-title":"Cell"},{"key":"403_CR140","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.semcancer.2012.04.001","volume":"22","author":"C Scheel","year":"2012","unstructured":"Scheel, C. & Weinberg, R. A. Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Semin. Cancer Biol. 22, 396\u2013403 (2012).","journal-title":"Semin. Cancer Biol."},{"key":"403_CR141","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1158\/0008-5472.CAN-16-3292","volume":"77","author":"A Dongre","year":"2017","unstructured":"Dongre, A. et al. Epithelial-to-mesenchymal transition contributes to immunosuppression in breast carcinomas. Cancer Res. 77, 3982\u20133989 (2017).","journal-title":"Cancer Res."},{"key":"403_CR142","doi-asserted-by":"crossref","first-page":"aau8544","DOI":"10.1126\/scisignal.aau8544","volume":"12","author":"Y Katsuno","year":"2019","unstructured":"Katsuno, Y. et al. Chronic TGF-\u03b2 exposure drives stabilized EMT, tumor stemness, and cancer drug resistance with vulnerability to bitopic mTOR inhibition. Sci. Signal. 12, aau8544 (2019).","journal-title":"Sci. Signal."},{"key":"403_CR143","doi-asserted-by":"crossref","first-page":"714","DOI":"10.3390\/cancers11050714","volume":"11","author":"R Soundararajan","year":"2019","unstructured":"Soundararajan, R. et al. Targeting the interplay between epithelial-to-mesenchymal-transition and the immune system for effective immunotherapy. Cancers 11, 714 (2019).","journal-title":"Cancers"},{"key":"403_CR144","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/1878-0261.12093","volume":"11","author":"S Terry","year":"2017","unstructured":"Terry, S. et al. New insights into the role of EMT in tumor immune escape. Mol. Oncol. 11, 824\u2013846 (2017).","journal-title":"Mol. Oncol."},{"key":"403_CR145","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s40425-018-0493-9","volume":"7","author":"E Dodagatta-Marri","year":"2019","unstructured":"Dodagatta-Marri, E. et al. \u03b1-PD-1 therapy elevates Treg\/Th balance and increases tumor cell pSmad3 that are both targeted by \u03b1-TGF\u03b2 antibody to promote durable rejection and immunity in squamous cell carcinomas. J. Immunother. Cancer 7, 62 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"403_CR146","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.canlet.2019.10.013","volume":"468","author":"Y Jiang","year":"2020","unstructured":"Jiang, Y. & Zhan, H. Communication between EMT and PD-L1 signaling: new insights into tumor immune evasion. Cancer Lett. 468, 72\u201381 (2020).","journal-title":"Cancer Lett."},{"key":"403_CR147","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/14737140.2020.1732211","volume":"20","author":"SM Reddy","year":"2020","unstructured":"Reddy, S. M., Carroll, E. & Nanda, R. Atezolizumab for the treatment of breast cancer. Expert. Rev. Anticancer Ther. 20, 151\u2013158 (2020).","journal-title":"Expert. Rev. Anticancer Ther."},{"key":"403_CR148","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","volume":"21","author":"P Schmid","year":"2020","unstructured":"Schmid, P. et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 21, 44\u201359 (2020).","journal-title":"Lancet Oncol."},{"key":"403_CR149","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.1038\/onc.2010.215","volume":"29","author":"A Singh","year":"2010","unstructured":"Singh, A. & Settleman, J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29, 4741\u20134751 (2010).","journal-title":"Oncogene"},{"key":"403_CR150","doi-asserted-by":"crossref","first-page":"6195","DOI":"10.1038\/s41388-018-0378-x","volume":"37","author":"J van Staalduinen","year":"2018","unstructured":"van Staalduinen, J., Baker, D., ten Dijke, P. & van Dam, H. Epithelial-mesenchymal-transition-inducing transcription factors: new targets for tackling chemoresistance in cancer? Oncogene 37, 6195\u20136211 (2018).","journal-title":"Oncogene"},{"key":"403_CR151","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nature15748","volume":"527","author":"KR Fischer","year":"2015","unstructured":"Fischer, K. R. et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 527, 472\u2013476 (2015).","journal-title":"Nature"},{"key":"403_CR152","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.cell.2015.01.043","volume":"160","author":"N Oshimori","year":"2015","unstructured":"Oshimori, N., Oristian, D. & Fuchs, E. TGF-\u03b2 promotes heterogeneity and drug resistance in squamous cell carcinoma. Cell 160, 963\u2013976 (2015).","journal-title":"Cell"},{"key":"403_CR153","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.3390\/ijms19124036","volume":"19","author":"T Nunes","year":"2018","unstructured":"Nunes, T. et al. Targeting cancer stem cells to overcome chemoresistance. Int. J. Mol. Sci. 19, 4036 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"403_CR154","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.3390\/cancers11101569","volume":"11","author":"ML De Angelis","year":"2019","unstructured":"De Angelis, M. L., Francescangeli, F. & Zeuner, A. Breast cancer stem cells as drivers of tumor chemoresistance, dormancy and relapse: new challenges and therapeutic opportunities. Cancers 11, 1569 (2019).","journal-title":"Cancers"},{"key":"403_CR155","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.semcancer.2018.11.006","volume":"53","author":"TB Steinbichler","year":"2018","unstructured":"Steinbichler, T. B. et al. Therapy resistance mediated by cancer stem cells. Semin. Cancer Biol. 53, 156\u2013167 (2018).","journal-title":"Semin. Cancer Biol."},{"key":"403_CR156","first-page":"5627","volume":"62","author":"KB Ewan","year":"2002","unstructured":"Ewan, K. B. et al. Transforming growth factor-\u03b21 mediates cellular response to DNA damage in situ. Cancer Res. 62, 5627\u20135631 (2002).","journal-title":"Cancer Res."},{"key":"403_CR157","first-page":"3645","volume":"56","author":"AB Glick","year":"1996","unstructured":"Glick, A. B., Weinberg, W. C., Wu, I. H., Quan, W. & Yuspa, S. H. Transforming growth factor \u03b21 suppresses genomic instability independent of a G1 arrest, p53, and Rb. Cancer Res. 56, 3645\u20133650 (1996).","journal-title":"Cancer Res."},{"key":"403_CR158","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1016\/j.celrep.2016.11.022","volume":"17","author":"V Comaills","year":"2016","unstructured":"Comaills, V. et al. Genomic instability is induced by persistent proliferation of cells undergoing epithelial-to-mesenchymal transition. Cell Rep. 17, 2632\u20132647 (2016).","journal-title":"Cell Rep."},{"key":"403_CR159","volume":"6","author":"D Pal","year":"2017","unstructured":"Pal, D. et al. TGF-\u03b2 reduces DNA ds-break repair mechanisms to heighten genetic diversity and adaptability of CD44+\/CD24- cancer cells. elife 6, e21615 (2017).","journal-title":"elife"},{"key":"403_CR160","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1126\/science.aaa6806","volume":"348","author":"I Martincorena","year":"2015","unstructured":"Martincorena, I. et al. Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science 348, 880\u2013886 (2015).","journal-title":"Science"},{"key":"403_CR161","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nature10755","volume":"482","author":"H Matsushita","year":"2012","unstructured":"Matsushita, H. et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482, 400\u2013404 (2012).","journal-title":"Nature"},{"key":"403_CR162","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrc.2015.5","volume":"16","author":"MG Morvan","year":"2016","unstructured":"Morvan, M. G. & Lanier, L. L. NK cells and cancer: you can teach innate cells new tricks. Nat. Rev. Cancer 16, 7\u201319 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"403_CR163","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1557372","volume":"8","author":"TL Trinh","year":"2019","unstructured":"Trinh, T. L. et al. Immune evasion by TGF\u03b2-induced miR-183 repression of MICA\/B expression in human lung tumor cells. Oncoimmunology 8, e1557372 (2019).","journal-title":"Oncoimmunology"},{"key":"403_CR164","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1158\/0008-5472.CAN-08-0215","volume":"68","author":"JS Nam","year":"2008","unstructured":"Nam, J. S. et al. An anti-transforming growth factor \u03b2 antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res. 68, 3835\u20133843 (2008).","journal-title":"Cancer Res."},{"key":"403_CR165","doi-asserted-by":"crossref","first-page":"7596","DOI":"10.1158\/0008-5472.CAN-04-1627","volume":"64","author":"MA Friese","year":"2004","unstructured":"Friese, M. A. et al. RNA interference targeting transforming growth factor-\u03b2 enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res. 64, 7596\u20137603 (2004).","journal-title":"Cancer Res."},{"key":"403_CR166","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.3389\/fimmu.2019.02689","volume":"10","author":"M Lazarova","year":"2019","unstructured":"Lazarova, M. & Steinle, A. Impairment of NKG2D-mediated tumor immunity by TGF-\u03b2. Front. Immunol. 10, 2689 (2019).","journal-title":"Front. Immunol."},{"key":"403_CR167","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.4049\/jimmunol.1502658","volume":"197","author":"S Sadallah","year":"2016","unstructured":"Sadallah, S. et al. Platelet-derived ectosomes reduce NK cell function. J. Immunol. 197, 1663\u20131671 (2016).","journal-title":"J. Immunol."},{"key":"403_CR168","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2176\/nmc.36.789","volume":"36","author":"H Naganuma","year":"1996","unstructured":"Naganuma, H. et al. Transforming growth factor-\u03b2 inhibits interferon-Gamma secretion by lymphokine-activated killer cells stimulated with tumor cells. Neurol. Med. Chir. 36, 789\u2013795 (1996).","journal-title":"Neurol. Med. Chir."},{"key":"403_CR169","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1101\/gad.314617.118","volume":"32","author":"H Gonzalez","year":"2018","unstructured":"Gonzalez, H., Hagerling, C. & Werb, Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 32, 1276\u20131284 (2018).","journal-title":"Genes Dev."},{"key":"403_CR170","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1101\/gad.210427.112","volume":"27","author":"CE Wong","year":"2013","unstructured":"Wong, C. E. et al. Inflammation and HRas signaling control epithelial-mesenchymal transition during skin tumor progression. Genes Dev. 27, 670\u2013682 (2013).","journal-title":"Genes Dev."},{"key":"403_CR171","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","volume":"140","author":"SI Grivennikov","year":"2010","unstructured":"Grivennikov, S. I., Greten, F. R. & Karin, M. Immunity, inflammation, and cancer. Cell 140, 883\u2013899 (2010).","journal-title":"Cell"},{"key":"403_CR172","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1471-4906(02)02302-5","volume":"23","author":"A Mantovani","year":"2002","unstructured":"Mantovani, A., Sozzani, S., Locati, M., Allavena, P. & Sica, A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23, 549\u2013555 (2002).","journal-title":"Trends Immunol."},{"key":"403_CR173","first-page":"59","volume":"78","author":"R Hildenbrand","year":"1998","unstructured":"Hildenbrand, R. et al. Transforming growth factor-\u03b2 stimulates urokinase expression in tumor-associated macrophages of the breast. Lab. Invest. 78, 59\u201371 (1998).","journal-title":"Lab. Invest."},{"key":"403_CR174","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1387\/ijdb.113371dl","volume":"55","author":"D Laoui","year":"2011","unstructured":"Laoui, D. et al. Tumor-associated macrophages in breast cancer: distinct subsets, distinct functions. Int. J. Dev. Biol. 55, 861\u2013867 (2011).","journal-title":"Int. J. Dev. Biol."},{"key":"403_CR175","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1038\/onc.2010.619","volume":"30","author":"TJ Standiford","year":"2011","unstructured":"Standiford, T. J. et al. TGF-\u03b2-induced IRAK-M expression in tumor-associated macrophages regulates lung tumor growth. Oncogene 30, 2475\u20132484 (2011).","journal-title":"Oncogene"},{"key":"403_CR176","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ccr.2009.06.017","volume":"16","author":"ZG Fridlender","year":"2009","unstructured":"Fridlender, Z. G. et al. Polarization of tumor-associated neutrophil phenotype by TGF-\u03b2: \u201cN1\u201d versus \u201cN2\u201d TAN. Cancer Cell 16, 183\u2013194 (2009).","journal-title":"Cancer Cell"},{"key":"403_CR177","doi-asserted-by":"crossref","first-page":"240","DOI":"10.4049\/jimmunol.182.1.240","volume":"182","author":"H Li","year":"2009","unstructured":"Li, H., Han, Y., Guo, Q., Zhang, M. & Cao, X. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-\u03b21. J. Immunol. 182, 240\u2013249 (2009).","journal-title":"J. Immunol."},{"key":"403_CR178","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/eji.1830270709","volume":"27","author":"M Takeuchi","year":"1997","unstructured":"Takeuchi, M., Kosiewicz, M. M., Alard, P. & Streilein, J. W. On the mechanisms by which transforming growth factor-\u03b22 alters antigen-presenting abilities of macrophages on T cell activation. Eur. J. Immunol. 27, 1648\u20131656 (1997).","journal-title":"Eur. J. Immunol."},{"key":"403_CR179","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/1523-1747.ep12469761","volume":"96","author":"A Demidem","year":"1991","unstructured":"Demidem, A., Taylor, J. R., Grammer, S. F. & Streilein, J. W. Comparison of effects of transforming growth factor-\u03b2 and cyclosporin A on antigen-presenting cells of blood and epidermis. J. Invest. Dermatol. 96, 401\u2013407 (1991).","journal-title":"J. Invest. Dermatol."},{"key":"403_CR180","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.cytogfr.2015.06.002","volume":"26","author":"P Seeger","year":"2015","unstructured":"Seeger, P., Musso, T. & Sozzani, S. The TGF-\u03b2 superfamily in dendritic cell biology. Cytokine Growth Factor Rev. 26, 647\u2013657 (2015).","journal-title":"Cytokine Growth Factor Rev."},{"key":"403_CR181","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1046\/j.1365-2567.1999.00915.x","volume":"98","author":"A Siegert","year":"1999","unstructured":"Siegert, A., Denkert, C., Leclere, A. & Hauptmann, S. Suppression of the reactive oxygen intermediates production of human macrophages by colorectal adenocarcinoma cell lines. Immunology 98, 551\u2013556 (1999).","journal-title":"Immunology"},{"key":"403_CR182","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.4049\/jimmunol.146.6.1849","volume":"146","author":"BJ Nelson","year":"1991","unstructured":"Nelson, B. J., Ralph, P., Green, S. J. & Nacy, C. A. Differential susceptibility of activated macrophage cytotoxic effector reactions to the suppressive effects of transforming growth factor-\u03b21. J. Immunol. 146, 1849\u20131857 (1991).","journal-title":"J. Immunol."},{"key":"403_CR183","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ccr.2007.12.004","volume":"13","author":"L Yang","year":"2008","unstructured":"Yang, L. et al. Abrogation of TGF \u03b2 signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 13, 23\u201335 (2008).","journal-title":"Cancer Cell"},{"key":"403_CR184","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/ni.3396","volume":"17","author":"J Mohammed","year":"2016","unstructured":"Mohammed, J. et al. Stromal cells control the epithelial residence of DCs and memory T cells by regulated activation of TGF-\u03b2. Nat. Immunol. 17, 414\u2013421 (2016).","journal-title":"Nat. Immunol."},{"key":"403_CR185","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ccell.2016.06.003","volume":"30","author":"EW Roberts","year":"2016","unstructured":"Roberts, E. W. et al. Critical role for CD103+\/CD141+ dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma. Cancer Cell 30, 324\u2013336 (2016).","journal-title":"Cancer Cell"},{"key":"403_CR186","first-page":"1860","volume":"63","author":"JJ Kobie","year":"2003","unstructured":"Kobie, J. J. et al. Transforming growth factor \u03b2 inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. Cancer Res. 63, 1860\u20131864 (2003).","journal-title":"Cancer Res."},{"key":"403_CR187","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.4049\/jimmunol.164.5.2285","volume":"164","author":"K Sato","year":"2000","unstructured":"Sato, K. et al. TGF-\u03b21 reciprocally controls chemotaxis of human peripheral blood monocyte-derived dendritic cells via chemokine receptors. J. Immunol. 164, 2285\u20132295 (2000).","journal-title":"J. Immunol."},{"key":"403_CR188","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cyto.2018.04.023","volume":"110","author":"R Gujar","year":"2018","unstructured":"Gujar, R. & Sen, P. Transforming growth factor-\u03b21 impairs lymph node homing of dendritic cells by downregulating C-type lectin receptor-2 expression. Cytokine 110, 39\u201343 (2018).","journal-title":"Cytokine"},{"key":"403_CR189","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/mi.2016.94","volume":"10","author":"TM Fenton","year":"2017","unstructured":"Fenton, T. M. et al. Inflammatory cues enhance TGF\u03b2 activation by distinct subsets of human intestinal dendritic cells via integrin \u03b1v\u03b28. Mucosal Immunol. 10, 624\u2013634 (2017).","journal-title":"Mucosal Immunol."},{"key":"403_CR190","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1084\/jem.20070590","volume":"204","author":"JL Coombes","year":"2007","unstructured":"Coombes, J. L. et al. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-\u03b2 and retinoic acid-dependent mechanism. J. Exp. Med. 204, 1757\u20131764 (2007).","journal-title":"J. Exp. Med."},{"key":"403_CR191","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0065-230X(03)90004-2","volume":"90","author":"J Wu","year":"2003","unstructured":"Wu, J. & Lanier, L. L. Natural killer cells and cancer. Adv. Cancer Res. 90, 127\u2013156 (2003).","journal-title":"Adv. Cancer Res."},{"key":"403_CR192","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.it.2019.11.004","volume":"41","author":"E Lugli","year":"2020","unstructured":"Lugli, E., Galletti, G., Boi, S. K. & Youngblood, B. A. Stem, effector, and hybrid states of memory CD8+ T cells. Trends Immunol. 41, 17\u201328 (2020).","journal-title":"Trends Immunol."},{"key":"403_CR193","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/00002371-200501000-00007","volume":"28","author":"J Zhou","year":"2005","unstructured":"Zhou, J., Dudley, M. E., Rosenberg, S. A. & Robbins, P. F. Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. J. Immunother. 28, 53\u201362 (2005).","journal-title":"J. Immunother."},{"key":"403_CR194","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/imr.12243","volume":"263","author":"S Gill","year":"2015","unstructured":"Gill, S. & June, C. H. Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. Immunol. Rev. 263, 68\u201389 (2015).","journal-title":"Immunol. Rev."},{"key":"403_CR195","doi-asserted-by":"crossref","first-page":"5957","DOI":"10.1158\/0008-5472.CAN-06-4309","volume":"67","author":"N Ahmed","year":"2007","unstructured":"Ahmed, N. et al. Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res. 67, 5957\u20135964 (2007).","journal-title":"Cancer Res."},{"key":"403_CR196","doi-asserted-by":"crossref","first-page":"20140374","DOI":"10.1098\/rstb.2014.0374","volume":"370","author":"CH June","year":"2015","unstructured":"June, C. H. & Levine, B. L. T cell engineering as therapy for cancer and HIV: our synthetic future. Philos. Trans. R. Soc. Lond. B Biol. Sci. 370, 20140374 (2015).","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"403_CR197","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","volume":"36","author":"R Grosser","year":"2019","unstructured":"Grosser, R., Cherkassky, L., Chintala, N. & Adusumilli, P. S. Combination immunotherapy with CAR-T cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell 36, 471\u2013482 (2019).","journal-title":"Cancer Cell"},{"key":"403_CR198","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41591-018-0197-1","volume":"24","author":"RN Amaria","year":"2018","unstructured":"Amaria, R. N. et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat. Med. 24, 1649\u20131654 (2018).","journal-title":"Nat. Med."},{"key":"403_CR199","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350\u20131355 (2018).","journal-title":"Science"},{"key":"403_CR200","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1073\/pnas.90.2.770","volume":"90","author":"AB Kulkarni","year":"1993","unstructured":"Kulkarni, A. B. et al. Transforming growth factor \u03b21 null mutation in mice causes excessive inflammatory response and early death. Proc. Natl Acad. Sci. USA 90, 770\u2013774 (1993).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"403_CR201","doi-asserted-by":"crossref","first-page":"12215","DOI":"10.1073\/pnas.92.26.12215","volume":"92","author":"RJ Diebold","year":"1995","unstructured":"Diebold, R. J. et al. Early-onset multifocal inflammation in the transforming growth factor \u03b21-null mouse is lymphocyte mediated. Proc. Natl Acad. Sci. USA 92, 12215\u201312219 (1995).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"403_CR202","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/359693a0","volume":"359","author":"MM Shull","year":"1992","unstructured":"Shull, M. M. et al. Targeted disruption of the mouse transforming growth factor-\u03b21 gene results in multifocal inflammatory disease. Nature 359, 693\u2013699 (1992).","journal-title":"Nature"},{"key":"403_CR203","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/nm1001-1118","volume":"7","author":"L Gorelik","year":"2001","unstructured":"Gorelik, L. & Flavell, R. A. Immune-mediated eradication of tumors through the blockade of transforming growth factor-\u03b2 signaling in T cells. Nat. Med. 7, 1118\u20131122 (2001).","journal-title":"Nat. Med."},{"key":"403_CR204","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252\u2013264 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"403_CR205","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1189\/jlb.1211639","volume":"92","author":"SV Novitskiy","year":"2012","unstructured":"Novitskiy, S. V. et al. Deletion of TGF-\u03b2 signaling in myeloid cells enhances their anti-tumorigenic properties. J. Leukoc. Biol. 92, 641\u2013651 (2012).","journal-title":"J. Leukoc. Biol."},{"key":"403_CR206","doi-asserted-by":"crossref","first-page":"5666","DOI":"10.4049\/jimmunol.175.9.5666","volume":"175","author":"IK Park","year":"2005","unstructured":"Park, I. K., Shultz, L. D., Letterio, J. J. & Gorham, J. D. TGF-\u03b21 inhibits T-bet induction by IFN-\u03b3 in murine CD4+ T cells through the protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-1. J. Immunol. 175, 5666\u20135674 (2005).","journal-title":"J. Immunol."},{"key":"403_CR207","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/00024382-200115030-00006","volume":"15","author":"MA Choudhry","year":"2001","unstructured":"Choudhry, M. A., Sir, O. & Sayeed, M. M. TGF-\u03b2 abrogates TCR-mediated signaling by upregulating tyrosine phosphatases in T cells. Shock 15, 193\u2013199 (2001).","journal-title":"Shock"},{"key":"403_CR208","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.4049\/jimmunol.180.3.1490","volume":"180","author":"L Das","year":"2008","unstructured":"Das, L. & Levine, A. D. TGF-\u03b2 inhibits IL-2 production and promotes cell cycle arrest in TCR-activated effector\/memory T cells in the presence of sustained TCR signal transduction. J. Immunol. 180, 1490\u20131498 (2008).","journal-title":"J. Immunol."},{"key":"403_CR209","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccr.2005.10.012","volume":"8","author":"DA Thomas","year":"2005","unstructured":"Thomas, D. A. & Massagu\u00e9, J. TGF-\u03b2 directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8, 369\u2013380 (2005).","journal-title":"Cancer Cell"},{"key":"403_CR210","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.immuni.2015.11.008","volume":"43","author":"LK Mackay","year":"2015","unstructured":"Mackay, L. K. et al. T-box transcription factors combine with the cytokines TGF-\u03b2 and IL-15 to control tissue-resident memory T cell fate. Immunity 43, 1101\u20131111 (2015).","journal-title":"Immunity"},{"key":"403_CR211","doi-asserted-by":"crossref","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","volume":"6","author":"PS Adusumilli","year":"2014","unstructured":"Adusumilli, P. S. et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci. Transl Med. 6, 261ra151 (2014).","journal-title":"Sci. Transl Med."},{"key":"403_CR212","doi-asserted-by":"crossref","first-page":"99048","DOI":"10.1172\/jci.insight.99048","volume":"3","author":"D Wang","year":"2018","unstructured":"Wang, D. et al. Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity. JCI Insight 3, 99048 (2018).","journal-title":"JCI Insight"},{"key":"403_CR213","doi-asserted-by":"crossref","first-page":"eaag1209","DOI":"10.1126\/scitranslmed.aag1209","volume":"9","author":"Y Yang","year":"2017","unstructured":"Yang, Y. et al. TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance. Sci. Transl Med. 9, eaag1209 (2017).","journal-title":"Sci. Transl Med."},{"key":"403_CR214","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1200\/JCO.2017.74.3179","volume":"36","author":"CM Bollard","year":"2018","unstructured":"Bollard, C. M. et al. Tumor-specific T-cells engineered to overcome tumor immune evasion induce clinical responses in patients with relapsed Hodgkin lymphoma. J. Clin. Oncol. 36, 1128\u20131139 (2018).","journal-title":"J. Clin. Oncol."},{"key":"403_CR215","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1084\/jem.188.12.2357","volume":"188","author":"K Hung","year":"1998","unstructured":"Hung, K. et al. The central role of CD4+ T cells in the antitumor immune response. J. Exp. Med. 188, 2357\u20132368 (1998).","journal-title":"J. Exp. Med."},{"key":"403_CR216","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.immuni.2005.02.003","volume":"22","author":"A Corthay","year":"2005","unstructured":"Corthay, A. et al. Primary antitumor immune response mediated by CD4+ T cells. Immunity 22, 371\u2013383 (2005).","journal-title":"Immunity"},{"key":"403_CR217","doi-asserted-by":"crossref","first-page":"5346","DOI":"10.1182\/blood-2006-10-051318","volume":"109","author":"A Perez-Diez","year":"2007","unstructured":"Perez-Diez, A. et al. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 109, 5346\u20135354 (2007).","journal-title":"Blood"},{"key":"403_CR218","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3390\/cancers8080071","volume":"8","author":"KA Murphy","year":"2016","unstructured":"Murphy, K. A. & Griffith, T. S. CD8 T cell-independent antitumor response and its potential for treatment of malignant gliomas. Cancers 8, 71 (2016).","journal-title":"Cancers"},{"key":"403_CR219","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.immuni.2006.07.012","volume":"25","author":"JC Marie","year":"2006","unstructured":"Marie, J. C., Liggitt, D. & Rudensky, A. Y. Cellular mechanisms of fatal early-onset autoimmunity in mice with the T cell-specific targeting of transforming growth factor-\u03b2 receptor. Immunity 25, 441\u2013454 (2006).","journal-title":"Immunity"},{"key":"403_CR220","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature04754","volume":"441","author":"PR Mangan","year":"2006","unstructured":"Mangan, P. R. et al. Transforming growth factor-\u03b2 induces development of the TH17 lineage. Nature 441, 231\u2013234 (2006).","journal-title":"Nature"},{"key":"403_CR221","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.immuni.2011.04.019","volume":"35","author":"MK Donkor","year":"2011","unstructured":"Donkor, M. K. et al. T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-\u03b21 cytokine. Immunity 35, 123\u2013134 (2011).","journal-title":"Immunity"},{"key":"403_CR222","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/imm.13058","volume":"157","author":"MA Moreno Ayala","year":"2019","unstructured":"Moreno Ayala, M. A., Li, Z. & DuPage, M. Treg programming and therapeutic reprogramming in cancer. Immunology 157, 198\u2013209 (2019).","journal-title":"Immunology"},{"key":"403_CR223","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1189\/jlb.0606409","volume":"81","author":"N Ralainirina","year":"2007","unstructured":"Ralainirina, N. et al. Control of NK cell functions by CD4+CD25+ regulatory T cells. J. Leukoc. Biol. 81, 144\u2013153 (2007).","journal-title":"J. Leukoc. Biol."},{"key":"403_CR224","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41590-018-0051-0","volume":"19","author":"D Zemmour","year":"2018","unstructured":"Zemmour, D. et al. Single-cell gene expression reveals a landscape of regulatory T cell phenotypes shaped by the TCR. Nat. Immunol. 19, 291\u2013301 (2018).","journal-title":"Nat. Immunol."},{"key":"403_CR225","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1158\/2326-6066.CIR-18-0098","volume":"6","author":"V Cremasco","year":"2018","unstructured":"Cremasco, V. et al. FAP delineates heterogeneous and functionally divergent stromal cells in immune-excluded breast tumors. Cancer Immunol. Res. 6, 1472\u20131485 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"403_CR226","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1414129","volume":"7","author":"M Boesch","year":"2018","unstructured":"Boesch, M. et al. Interleukin 7-expressing fibroblasts promote breast cancer growth through sustenance of tumor cell stemness. Oncoimmunology 7, e1414129 (2018).","journal-title":"Oncoimmunology"},{"key":"403_CR227","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ccell.2018.01.011","volume":"33","author":"A Costa","year":"2018","unstructured":"Costa, A. et al. Fibroblast heterogeneity and immunosuppressive environment in human breast cancer. Cancer Cell 33, 463\u2013479 (2018).","journal-title":"Cancer Cell"},{"key":"403_CR228","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1158\/2159-8290.CD-19-0094","volume":"9","author":"E Elyada","year":"2019","unstructured":"Elyada, E. et al. Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. Cancer Discov. 9, 1102\u20131123 (2019).","journal-title":"Cancer Discov."},{"key":"403_CR229","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1084\/jem.20162024","volume":"214","author":"D Ohlund","year":"2017","unstructured":"Ohlund, D. et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J. Exp. Med. 214, 579\u2013596 (2017).","journal-title":"J. Exp. Med."},{"key":"403_CR230","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ccr.2012.08.013","volume":"22","author":"A Calon","year":"2012","unstructured":"Calon, A. et al. Dependency of colorectal cancer on a TGF-\u03b2-driven program in stromal cells for metastasis initiation. Cancer Cell 22, 571\u2013584 (2012).","journal-title":"Cancer Cell"},{"key":"403_CR231","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/ng.3225","volume":"47","author":"A Calon","year":"2015","unstructured":"Calon, A. et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat. Genet. 47, 320\u2013329 (2015).","journal-title":"Nat. Genet."},{"key":"403_CR232","doi-asserted-by":"crossref","first-page":"20212","DOI":"10.1073\/pnas.1320318110","volume":"110","author":"C Feig","year":"2013","unstructured":"Feig, C. et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc. Natl Acad. Sci. USA 110, 20212\u201320217 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"403_CR233","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1158\/2326-6066.CIR-14-0002","volume":"2","author":"DT Fearon","year":"2014","unstructured":"Fearon, D. T. The carcinoma-associated fibroblast expressing fibroblast activation protein and escape from immune surveillance. Cancer Immunol. Res. 2, 187\u2013193 (2014).","journal-title":"Cancer Immunol. Res."},{"key":"403_CR234","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-03347-0","volume":"9","author":"MA Lakins","year":"2018","unstructured":"Lakins, M. A., Ghorani, E., Munir, H., Martins, C. P. & Shields, J. D. Cancer-associated fibroblasts induce antigen-specific deletion of CD8+ T cells to protect tumour cells. Nat. Commun. 9, 948 (2018).","journal-title":"Nat. Commun."},{"key":"403_CR235","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.exer.2015.07.009","volume":"142","author":"B Hinz","year":"2016","unstructured":"Hinz, B. Myofibroblasts. Exp. Eye Res. 142, 56\u201370 (2016).","journal-title":"Exp. Eye Res."},{"key":"403_CR236","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.semcancer.2013.12.008","volume":"25","author":"A Calon","year":"2014","unstructured":"Calon, A., Tauriello, D. V. & Batlle, E. TGF-\u03b2 in CAF-mediated tumor growth and metastasis. Semin. Cancer Biol. 25, 15\u201322 (2014).","journal-title":"Semin. Cancer Biol."},{"key":"403_CR237","doi-asserted-by":"crossref","first-page":"dmm029447","DOI":"10.1242\/dmm.029447","volume":"11","author":"VS LeBleu","year":"2018","unstructured":"LeBleu, V. S. & Kalluri, R. A peek into cancer-associated fibroblasts: origins, functions and translational impact. Dis. Model. Mech. 11, dmm029447 (2018).","journal-title":"Dis. Model. Mech."},{"key":"403_CR238","doi-asserted-by":"crossref","first-page":"36505","DOI":"10.1074\/jbc.274.51.36505","volume":"274","author":"JE Park","year":"1999","unstructured":"Park, J. E. et al. Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J. Biol. Chem. 274, 36505\u201336512 (1999).","journal-title":"J. Biol. Chem."},{"key":"403_CR239","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1016\/j.ajpath.2012.08.027","volume":"181","author":"M Yin","year":"2012","unstructured":"Yin, M. et al. TGF-\u03b2 signaling, activated stromal fibroblasts, and cysteine cathepsins B and L drive the invasive growth of human melanoma cells. Am. J. Pathol. 181, 2202\u20132216 (2012).","journal-title":"Am. J. Pathol."},{"key":"403_CR240","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1158\/1541-7786.MCR-13-0033-T","volume":"11","author":"HE Barker","year":"2013","unstructured":"Barker, H. E., Bird, D., Lang, G. & Erler, J. T. Tumor-secreted LOXL2 activates fibroblasts through FAK signaling. Mol. Cancer Res. 11, 1425\u20131436 (2013).","journal-title":"Mol. Cancer Res."},{"key":"403_CR241","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1172\/JCI94624","volume":"127","author":"Y Wei","year":"2017","unstructured":"Wei, Y. et al. Fibroblast-specific inhibition of TGF-\u03b21 signaling attenuates lung and tumor fibrosis. J. Clin. Invest. 127, 3675\u20133688 (2017).","journal-title":"J. Clin. Invest."},{"key":"403_CR242","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ccr.2005.08.010","volume":"8","author":"MJ Paszek","year":"2005","unstructured":"Paszek, M. J. et al. Tensional homeostasis and the malignant phenotype. Cancer Cell 8, 241\u2013254 (2005).","journal-title":"Cancer Cell"},{"key":"403_CR243","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1158\/1541-7786.MCR-12-0307","volume":"10","author":"GS Karagiannis","year":"2012","unstructured":"Karagiannis, G. S. et al. Cancer-associated fibroblasts drive the progression of metastasis through both paracrine and mechanical pressure on cancer tissue. Mol. Cancer Res. 10, 1403\u20131418 (2012).","journal-title":"Mol. Cancer Res."},{"key":"403_CR244","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.3389\/fimmu.2019.01835","volume":"10","author":"L Monteran","year":"2019","unstructured":"Monteran, L. & Erez, N. The dark side of fibroblasts: cancer-associated fibroblasts as mediators of immunosuppression in the tumor microenvironment. Front. Immunol. 10, 1835 (2019).","journal-title":"Front. Immunol."},{"key":"403_CR245","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","volume":"25","author":"BC Ozdemir","year":"2014","unstructured":"Ozdemir, B. C. et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25, 719\u2013734 (2014).","journal-title":"Cancer Cell"},{"key":"403_CR246","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1008415","volume":"15","author":"S Fereres","year":"2019","unstructured":"Fereres, S., Hatori, R., Hatori, M. & Kornberg, T. B. Cytoneme-mediated signaling essential for tumorigenesis. PLoS Genet. 15, e1008415 (2019).","journal-title":"PLoS Genet."},{"key":"403_CR247","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.gde.2017.02.010","volume":"45","author":"TB Kornberg","year":"2017","unstructured":"Kornberg, T. B. Distributing signaling proteins in space and time: the province of cytonemes. Curr. Opin. Genet. Dev. 45, 22\u201327 (2017).","journal-title":"Curr. Opin. Genet. Dev."},{"key":"403_CR248","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1126\/science.1090922","volume":"303","author":"NA Bhowmick","year":"2004","unstructured":"Bhowmick, N. A. et al. TGF-\u03b2 signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303, 848\u2013851 (2004).","journal-title":"Science"},{"key":"403_CR249","first-page":"1492","volume":"10","author":"SJ Kim","year":"1990","unstructured":"Kim, S. J. et al. Autoinduction of transforming growth factor \u03b21 is mediated by the AP-1 complex. Mol. Cell Biol. 10, 1492\u20131497 (1990).","journal-title":"Mol. Cell Biol."},{"key":"403_CR250","doi-asserted-by":"crossref","first-page":"38164","DOI":"10.18632\/oncotarget.9416","volume":"7","author":"KC Flanders","year":"2016","unstructured":"Flanders, K. C. et al. Quantitation of TGF-\u03b2 proteins in mouse tissues shows reciprocal changes in TGF-\u03b21 and TGF-\u03b23 in normal vs neoplastic mammary epithelium. Oncotarget 7, 38164\u201338179 (2016).","journal-title":"Oncotarget"},{"key":"403_CR251","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1242\/jcs.021683","volume":"121","author":"PS Acharya","year":"2008","unstructured":"Acharya, P. S. et al. Fibroblast migration is mediated by CD44-dependent TGF \u03b2 activation. J. Cell Sci. 121, 1393\u20131402 (2008).","journal-title":"J. Cell Sci."},{"key":"403_CR252","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1084\/jem.165.1.251","volume":"165","author":"AE Postlethwaite","year":"1987","unstructured":"Postlethwaite, A. E., Keski-Oja, J., Moses, H. L. & Kang, A. H. Stimulation of the chemotactic migration of human fibroblasts by transforming growth factor \u03b2. J. Exp. Med. 165, 251\u2013256 (1987).","journal-title":"J. Exp. Med."},{"key":"403_CR253","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201910515","volume":"11","author":"H Huang","year":"2019","unstructured":"Huang, H. et al. Targeting TGF\u03b2R2-mutant tumors exposes vulnerabilities to stromal TGF\u03b2 blockade in pancreatic cancer. EMBO Mol. Med. 11, e10515 (2019).","journal-title":"EMBO Mol. Med."},{"key":"403_CR254","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1158\/2159-8290.CD-18-0710","volume":"9","author":"G Biffi","year":"2019","unstructured":"Biffi, G. et al. IL1-induced JAK\/STAT signaling is antagonized by TGF\u03b2 to shape CAF heterogeneity in pancreatic ductal adenocarcinoma. Cancer Discov. 9, 282\u2013301 (2019).","journal-title":"Cancer Discov."},{"key":"403_CR255","doi-asserted-by":"crossref","first-page":"99911","DOI":"10.1172\/jci.insight.99911","volume":"3","author":"DS Foster","year":"2018","unstructured":"Foster, D. S., Jones, R. E., Ransom, R. C., Longaker, M. T. & Norton, J. A. The evolving relationship of wound healing and tumor stroma. JCI Insight 3, 99911 (2018).","journal-title":"JCI Insight"},{"key":"403_CR256","doi-asserted-by":"crossref","first-page":"6205","DOI":"10.1158\/0008-5472.CAN-16-0176","volume":"76","author":"L Alba-Castellon","year":"2016","unstructured":"Alba-Castellon, L. et al. Snail1-dependent activation of cancer-associated fibroblast controls epithelial tumor cell invasion and metastasis. Cancer Res. 76, 6205\u20136217 (2016).","journal-title":"Cancer Res."},{"key":"403_CR257","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/1878-0261.12080","volume":"11","author":"J Baulida","year":"2017","unstructured":"Baulida, J. Epithelial-to-mesenchymal transition transcription factors in cancer-associated fibroblasts. Mol. Oncol. 11, 847\u2013859 (2017).","journal-title":"Mol. Oncol."},{"key":"403_CR258","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1172\/JCI39104","volume":"119","author":"R Kalluri","year":"2009","unstructured":"Kalluri, R. & Weinberg, R. A. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 119, 1420\u20131428 (2009).","journal-title":"J. Clin. Invest."},{"key":"403_CR259","doi-asserted-by":"crossref","first-page":"196","DOI":"10.2174\/1574888X09666140213154144","volume":"9","author":"W Yu","year":"2014","unstructured":"Yu, W. et al. The endothelial-mesenchymal transition (EndMT) and tissue regeneration. Curr. Stem Cell Res. Ther. 9, 196\u2013204 (2014).","journal-title":"Curr. Stem Cell Res. Ther."},{"key":"403_CR260","doi-asserted-by":"crossref","first-page":"F703","DOI":"10.1152\/ajprenal.00254.2005","volume":"290","author":"W Qi","year":"2006","unstructured":"Qi, W. et al. TGF-\u03b21 induces IL-8 and MCP-1 through a connective tissue growth factor-independent pathway. Am. J. Physiol. Renal. Physiol. 290, F703\u2013709 (2006).","journal-title":"Am. J. Physiol. Renal. Physiol."},{"key":"403_CR261","volume":"7","author":"J Shi","year":"2017","unstructured":"Shi, J. et al. Targeted blockade of TGF-\u03b2 and IL-6\/JAK2\/STAT3 pathways inhibits lung cancer growth promoted by bone marrow-derived myofibroblasts. Sci. Rep. 7, 8660 (2017).","journal-title":"Sci. Rep."},{"key":"403_CR262","doi-asserted-by":"crossref","first-page":"35861","DOI":"10.1074\/jbc.M109.014639","volume":"284","author":"T Matsumura","year":"2009","unstructured":"Matsumura, T. et al. Regulation of transforming growth factor-\u03b2-dependent cyclooxygenase-2 expression in fibroblasts. J. Biol. Chem. 284, 35861\u201335871 (2009).","journal-title":"J. Biol. Chem."},{"key":"403_CR263","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/onc.2016.252","volume":"36","author":"PF Yu","year":"2017","unstructured":"Yu, P. F. et al. Downregulation of CXCL12 in mesenchymal stromal cells by TGF\u03b2 promotes breast cancer metastasis. Oncogene 36, 840\u2013849 (2017).","journal-title":"Oncogene"},{"key":"403_CR264","doi-asserted-by":"crossref","first-page":"4428","DOI":"10.1038\/s41388-018-0263-7","volume":"37","author":"DK Ahirwar","year":"2018","unstructured":"Ahirwar, D. K. et al. Fibroblast-derived CXCL12 promotes breast cancer metastasis by facilitating tumor cell intravasation. Oncogene 37, 4428\u20134442 (2018).","journal-title":"Oncogene"},{"key":"403_CR265","doi-asserted-by":"crossref","first-page":"6271","DOI":"10.1016\/S0021-9258(17)37365-9","volume":"269","author":"L Pertovaara","year":"1994","unstructured":"Pertovaara, L. et al. Vascular endothelial growth factor is induced in response to transforming growth factor-\u03b2 in fibroblastic and epithelial cells. J. Biol. Chem. 269, 6271\u20136274 (1994).","journal-title":"J. Biol. Chem."},{"key":"403_CR266","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/339058a0","volume":"339","author":"J Folkman","year":"1989","unstructured":"Folkman, J., Watson, K., Ingber, D. & Hanahan, D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339, 58\u201361 (1989).","journal-title":"Nature"},{"key":"403_CR267","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1242\/dev.121.6.1845","volume":"121","author":"MC Dickson","year":"1995","unstructured":"Dickson, M.C. et al. Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice. Development 121, 1845\u2013854 (1995).","journal-title":"Development"},{"key":"403_CR268","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S1097-2765(03)00386-1","volume":"12","author":"MJ Goumans","year":"2003","unstructured":"Goumans, M. J. et al. Activin receptor- like kinase (ALK)1 is an antagonistic mediator of lateral TGF\u03b2\/ALK5 signaling. Mol. Cell 12, 817\u2013828 (2003).","journal-title":"Mol. Cell"},{"key":"403_CR269","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.devcel.2012.02.005","volume":"22","author":"B Larrivee","year":"2012","unstructured":"Larrivee, B. et al. ALK1 signaling inhibits angiogenesis by cooperating with the Notch pathway. Dev. Cell 22, 489\u2013500 (2012).","journal-title":"Dev. Cell"},{"key":"403_CR270","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1083\/jcb.106.4.1375","volume":"106","author":"JA Madri","year":"1988","unstructured":"Madri, J. A., Pratt, B. M. & Tucker, A. M. Phenotypic modulation of endothelial cells by transforming growth factor-\u03b2 depends upon the composition and organization of the extracellular matrix. J. Cell Biol. 106, 1375\u20131384 (1988).","journal-title":"J. Cell Biol."},{"key":"403_CR271","doi-asserted-by":"crossref","first-page":"7540","DOI":"10.1158\/1078-0432.CCR-04-0632","volume":"10","author":"T Hayashi","year":"2004","unstructured":"Hayashi, T. et al. Transforming growth factor \u03b2 receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. Clin. Cancer Res. 10, 7540\u20137546 (2004).","journal-title":"Clin. Cancer Res."},{"key":"403_CR272","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-10946-y","volume":"10","author":"R Batlle","year":"2019","unstructured":"Batlle, R. et al. Regulation of tumor angiogenesis and mesenchymal-endothelial transition by p38\u03b1 through TGF-\u03b2 and JNK signaling. Nat. Commun. 10, 3071 (2019).","journal-title":"Nat. Commun."},{"key":"403_CR273","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1083\/jcb.111.2.731","volume":"111","author":"EY Yang","year":"1990","unstructured":"Yang, E. Y. & Moses, H. L. Transforming growth factor \u03b21-induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane. J. Cell Biol. 111, 731\u2013741 (1990).","journal-title":"J. Cell Biol."},{"key":"403_CR274","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1097\/PGP.0b013e31824c23a4","volume":"31","author":"H Lin","year":"2012","unstructured":"Lin, H. et al. High immunohistochemical expression of TGF-\u03b21 predicts a poor prognosis in cervical cancer patients who harbor enriched endoglin microvessel density. Int. J. Gynecol. Pathol. 31, 482\u2013489 (2012).","journal-title":"Int. J. Gynecol. Pathol."},{"key":"403_CR275","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.3892\/ol.2015.3997","volume":"11","author":"GC Li","year":"2016","unstructured":"Li, G. C. et al. Mesenchymal stem cells promote tumor angiogenesis via the action of transforming growth factor \u03b21. Oncol. Lett. 11, 1089\u20131094 (2016).","journal-title":"Oncol. Lett."},{"key":"403_CR276","doi-asserted-by":"crossref","first-page":"a022210","DOI":"10.1101\/cshperspect.a022210","volume":"10","author":"MJ Goumans","year":"2018","unstructured":"Goumans, M. J. & ten Dijke, P. TGF-\u03b2 signaling in control of cardiovascular function. Cold Spring. Harb. Perspect. Biol. 10, a022210 (2018).","journal-title":"Cold Spring. Harb. Perspect. Biol."},{"key":"403_CR277","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1083\/jcb.111.2.757","volume":"111","author":"Y Sato","year":"1990","unstructured":"Sato, Y., Tsuboi, R., Lyons, R., Moses, H. & Rifkin, D. B. Characterization of the activation of latent TGF-\u03b2 by co-cultures of endothelial cells and pericytes or smooth muscle cells: a self-regulating system. J. Cell Biol. 111, 757\u2013763 (1990).","journal-title":"J. Cell Biol."},{"key":"403_CR278","volume":"4","author":"TE Walshe","year":"2009","unstructured":"Walshe, T. E. et al. TGF-\u03b2 is required for vascular barrier function, endothelial survival and homeostasis of the adult microvasculature. PLoS ONE 4, e5149 (2009).","journal-title":"PLoS ONE"},{"key":"403_CR279","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1161\/ATVBAHA.110.210492","volume":"30","author":"S He","year":"2010","unstructured":"He, S., Li, M., Ma, X., Lin, J. & Li, D. CD4+CD25+Foxp3+ regulatory T cells protect the proinflammatory activation of human umbilical vein endothelial cells. Arterioscler. Thromb. Vasc. Biol. 30, 2621\u20132630 (2010).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"403_CR280","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/s42255-019-0102-3","volume":"1","author":"PY Chen","year":"2019","unstructured":"Chen, P. Y. et al. Endothelial TGF-\u03b2 signalling drives vascular inflammation and atherosclerosis. Nat. Metab. 1, 912\u2013926 (2019).","journal-title":"Nat. Metab."},{"key":"403_CR281","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/sj.leu.2403355","volume":"18","author":"C Scavelli","year":"2004","unstructured":"Scavelli, C., Vacca, A., Di Pietro, G., Dammacco, F. & Ribatti, D. Crosstalk between angiogenesis and lymphangiogenesis in tumor progression. Leukemia 18, 1054\u20131058 (2004).","journal-title":"Leukemia"},{"key":"403_CR282","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrc863","volume":"2","author":"SA Stacker","year":"2002","unstructured":"Stacker, S. A., Achen, M. G., Jussila, L., Baldwin, M. E. & Alitalo, K. Lymphangiogenesis and cancer metastasis. Nat. Rev. Cancer 2, 573\u2013583 (2002).","journal-title":"Nat. Rev. Cancer"},{"key":"403_CR283","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1182\/blood-2009-07-235655","volume":"115","author":"K Niessen","year":"2010","unstructured":"Niessen, K., Zhang, G., Ridgway, J. B., Chen, H. & Yan, M. ALK1 signaling regulates early postnatal lymphatic vessel development. Blood 115, 1654\u20131661 (2010).","journal-title":"Blood"},{"key":"403_CR284","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/35070086","volume":"3","author":"J Seoane","year":"2001","unstructured":"Seoane, J. et al. TGF\u03b2 influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b. Nat. Cell Biol. 3, 400\u2013408 (2001).","journal-title":"Nat. Cell Biol."},{"key":"403_CR285","first-page":"1596","volume":"48","author":"RJ Coffey Jr.","year":"1988","unstructured":"Coffey, R. J. Jr. et al. Growth modulation of mouse keratinocytes by transforming growth factors. Cancer Res. 48, 1596\u20131602 (1988).","journal-title":"Cancer Res."},{"key":"403_CR286","doi-asserted-by":"crossref","first-page":"4254","DOI":"10.1073\/pnas.92.10.4254","volume":"92","author":"DF Pierce Jr.","year":"1995","unstructured":"Pierce, D. F. Jr. et al. Mammary tumor suppression by transforming growth factor \u03b21 transgene expression. Proc. Natl Acad. Sci. USA 92, 4254\u20134258 (1995).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"403_CR287","first-page":"367","volume":"1","author":"CL Arteaga","year":"1990","unstructured":"Arteaga, C. L. et al. Growth stimulation of human breast cancer cells with anti-transforming growth factor \u03b2 antibodies: evidence for negative autocrine regulation by transforming growth factor \u03b2. Cell Growth Differ. 1, 367\u2013374 (1990).","journal-title":"Cell Growth Differ."},{"key":"403_CR288","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0092-8674(90)90251-9","volume":"62","author":"M Laiho","year":"1990","unstructured":"Laiho, M., DeCaprio, J. A., Ludlow, J. W., Livingston, D. M. & Massagu\u00e9, J. Growth inhibition by TGF-\u03b2 linked to suppression of retinoblastoma protein phosphorylation. Cell 62, 175\u2013185 (1990).","journal-title":"Cell"},{"key":"403_CR289","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1126\/science.8475385","volume":"260","author":"A Koff","year":"1993","unstructured":"Koff, A., Ohtsuki, M., Polyak, K., Roberts, J. M. & Massagu\u00e9, J. Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF-\u03b2. Science 260, 536\u2013539 (1993).","journal-title":"Science"},{"key":"403_CR290","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1172\/JCI0215970","volume":"109","author":"RJ Akhurst","year":"2002","unstructured":"Akhurst, R. J. TGF-\u03b2 antagonists: why suppress a tumor suppressor? J. Clin. Invest. 109, 1533\u20131536 (2002).","journal-title":"J. Clin. Invest."},{"key":"403_CR291","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1172\/JCI116871","volume":"92","author":"CL Arteaga","year":"1993","unstructured":"Arteaga, C. L. et al. Anti-transforming growth factor (TGF)-\u03b2 antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell\/host TGF-\u03b2 interactions in human breast cancer progression. J. Clin. Invest. 92, 2569\u20132576 (1993).","journal-title":"J. Clin. Invest."},{"key":"403_CR292","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0125295","volume":"10","author":"J Igarashi","year":"2015","unstructured":"Igarashi, J. et al. Preclinical study of novel gene silencer pyrrole-imidazole polyamide targeting human TGF-\u03b21 promoter for hypertrophic scars in a common marmoset primate model. PLoS ONE 10, e0125295 (2015).","journal-title":"PLoS ONE"},{"key":"403_CR293","doi-asserted-by":"crossref","first-page":"944","DOI":"10.3171\/jns.1993.78.6.0944","volume":"78","author":"P Jachimczak","year":"1993","unstructured":"Jachimczak, P. et al. The effect of transforming growth factor-\u03b22-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma. J. Neurosurg. 78, 944\u2013951 (1993).","journal-title":"J. Neurosurg."},{"key":"403_CR294","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/neuonc\/now009","volume":"18","author":"AA Brandes","year":"2016","unstructured":"Brandes, A. A. et al. A phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. Neuro. Oncol. 18, 1146\u20131156 (2016).","journal-title":"Neuro. Oncol."},{"key":"403_CR295","doi-asserted-by":"crossref","first-page":"6659","DOI":"10.18632\/oncotarget.23795","volume":"9","author":"JM Yingling","year":"2018","unstructured":"Yingling, J. M. et al. Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-\u03b2 receptor type I inhibitor. Oncotarget 9, 6659\u20136677 (2018).","journal-title":"Oncotarget"},{"key":"403_CR296","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1124\/mol.62.1.65","volume":"62","author":"GJ Inman","year":"2002","unstructured":"Inman, G. J. et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-\u03b2 superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol. Pharmacol. 62, 65\u201374 (2002).","journal-title":"Mol. Pharmacol."},{"key":"403_CR297","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1161\/ATVBAHA.107.158030","volume":"28","author":"K Fu","year":"2008","unstructured":"Fu, K. et al. SM16, an orally active TGF-\u03b2 type I receptor inhibitor prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model. Arterioscler. Thromb. Vasc. Biol. 28, 665\u2013671 (2008).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"403_CR298","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.isci.2018.12.038","volume":"11","author":"EH Budi","year":"2019","unstructured":"Budi, E. H., Mamai, O., Hoffman, S., Akhurst, R. J. & Derynck, R. Enhanced TGF-\u03b2 signaling contributes to the insulin-induced angiogenic responses of endothelial cells. iScience 11, 474\u2013491 (2019).","journal-title":"iScience"},{"key":"403_CR299","doi-asserted-by":"crossref","first-page":"eaal4186","DOI":"10.1126\/scisignal.aal4186","volume":"10","author":"A Hamidi","year":"2017","unstructured":"Hamidi, A. et al. TGF-\u03b2 promotes PI3K-AKT signaling and prostate cancer cell migration through the TRAF6-mediated ubiquitylation of p85\u03b1. Sci. Signal. 10, eaal4186 (2017).","journal-title":"Sci. Signal."},{"key":"403_CR300","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1007\/s10637-019-00835-y","volume":"38","author":"SY Jung","year":"2020","unstructured":"Jung, S. Y. et al. Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 study. Invest. New Drugs 38, 812\u2013820 (2020).","journal-title":"Invest. New Drugs"},{"key":"403_CR301","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00280-019-03979-z","volume":"85","author":"SY Jung","year":"2019","unstructured":"Jung, S. Y. et al. Population pharmacokinetics of vactosertib, a new TGF-\u03b2 receptor type I inhibitor, in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 85, 173\u2013183 (2019).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"403_CR302","volume":"9","author":"JC Morris","year":"2014","unstructured":"Morris, J. C. et al. Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-\u03b2 (TGF\u03b2) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS ONE 9, e90353 (2014).","journal-title":"PLoS ONE"},{"key":"403_CR303","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/19420862.2015.1115166","volume":"8","author":"D Bedinger","year":"2016","unstructured":"Bedinger, D. et al. Development and characterization of human monoclonal antibodies that neutralize multiple TGF\u03b2 isoforms. MAbs 8, 389\u2013404 (2016).","journal-title":"MAbs"},{"key":"403_CR304","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.cytogfr.2009.07.002","volume":"20","author":"HG Laverty","year":"2009","unstructured":"Laverty, H. G., Wakefield, L. M., Occleston, N. L., O\u2019Kane, S. & Ferguson, M. W. TGF-\u03b23 and cancer: a review. Cytokine Growth Factor Rev. 20, 305\u2013317 (2009).","journal-title":"Cytokine Growth Factor Rev."},{"key":"403_CR305","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.3892\/ijo.2014.2679","volume":"45","author":"A Cohn","year":"2014","unstructured":"Cohn, A. et al. A phase I dose-escalation study to a predefined dose of a transforming growth factor-\u03b21 monoclonal antibody (T\u03b2M1) in patients with metastatic cancer. Int. J. Oncol. 45, 2221\u20132231 (2014).","journal-title":"Int. J. Oncol."},{"key":"403_CR306","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1158\/1078-0432.CCR-09-1634","volume":"16","author":"Z Zhong","year":"2010","unstructured":"Zhong, Z. et al. Anti-transforming growth factor \u03b2 receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells. Clin. Cancer Res. 16, 1191\u20131205 (2010).","journal-title":"Clin. Cancer Res."},{"key":"403_CR307","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00280-017-3245-5","volume":"79","author":"AW Tolcher","year":"2017","unstructured":"Tolcher, A. W. et al. A phase 1 study of anti-TGF\u03b2 receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 79, 673\u2013680 (2017).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"403_CR308","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1172\/JCI200215333","volume":"109","author":"YA Yang","year":"2002","unstructured":"Yang, Y. A. et al. Lifetime exposure to a soluble TGF-\u03b2 antagonist protects mice against metastasis without adverse side effects. J. Clin. Invest. 109, 1607\u20131615 (2002).","journal-title":"J. Clin. Invest."},{"key":"403_CR309","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.2174\/138920111798808383","volume":"12","author":"AP Hinck","year":"2011","unstructured":"Hinck, A. P. & O\u2019Connor-McCourt, M. D. Structures of TGF-\u03b2 receptor complexes: implications for function and therapeutic intervention using ligand traps. Curr. Pharm. Biotechnol. 12, 2081\u20132098 (2011).","journal-title":"Curr. Pharm. Biotechnol."},{"key":"403_CR310","doi-asserted-by":"crossref","first-page":"eaan5488","DOI":"10.1126\/scitranslmed.aan5488","volume":"10","author":"Y Lan","year":"2018","unstructured":"Lan, Y. et al. Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-\u03b2. Sci. Transl Med. 10, eaan5488 (2018).","journal-title":"Sci. Transl Med."},{"key":"403_CR311","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-02696-6","volume":"9","author":"R Ravi","year":"2018","unstructured":"Ravi, R. et al. Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGF\u03b2 enhance the efficacy of cancer immunotherapy. Nat. Commun. 9, 741 (2018).","journal-title":"Nat. Commun."},{"key":"403_CR312","doi-asserted-by":"crossref","first-page":"86087","DOI":"10.18632\/oncotarget.13343","volume":"7","author":"T Qin","year":"2016","unstructured":"Qin, T. et al. A novel highly potent trivalent TGF-\u03b2 receptor trap inhibits early-stage tumorigenesis and tumor cell invasion in murine Pten-deficient prostate glands. Oncotarget 7, 86087\u201386102 (2016).","journal-title":"Oncotarget"},{"key":"403_CR313","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1158\/1535-7163.MCT-12-0060","volume":"11","author":"JC Zwaagstra","year":"2012","unstructured":"Zwaagstra, J. C. et al. Engineering and therapeutic application of single-chain bivalent TGF-\u03b2 family traps. Mol. Cancer Ther. 11, 1477\u20131487 (2012).","journal-title":"Mol. Cancer Ther."},{"key":"403_CR314","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1426519","volume":"7","author":"KM Knudson","year":"2018","unstructured":"Knudson, K. M. et al. M7824, a novel bifunctional anti-PD-L1\/TGF\u03b2 trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine. Oncoimmunology 7, e1426519 (2018).","journal-title":"Oncoimmunology"},{"key":"403_CR315","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1158\/0008-5472.CAN-07-6390","volume":"68","author":"CC Park","year":"2008","unstructured":"Park, C. C., Zhang, H. J., Yao, E. S., Park, C. J. & Bissell, M. J. \u03b21 integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts. Cancer Res. 68, 4398\u20134405 (2008).","journal-title":"Cancer Res."},{"key":"403_CR316","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1158\/0008-5472.CAN-05-3071","volume":"66","author":"CC Park","year":"2006","unstructured":"Park, C. C. et al. \u03b21 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res. 66, 1526\u20131535 (2006).","journal-title":"Cancer Res."},{"key":"403_CR317","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1158\/0008-5472.CAN-07-2307","volume":"68","author":"LA Van Aarsen","year":"2008","unstructured":"Van Aarsen, L. A. et al. Antibody-mediated blockade of integrin \u03b1v\u03b26 inhibits tumor progression in vivo by a transforming growth factor-\u03b2-regulated mechanism. Cancer Res. 68, 561\u2013570 (2008).","journal-title":"Cancer Res."},{"key":"403_CR318","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1021\/acs.jmedchem.6b01711","volume":"60","author":"LM Miller","year":"2017","unstructured":"Miller, L. M., Pritchard, J. M., MacDonald, S. J. F., Jamieson, C. & Watson, A. J. B. Emergence of small-molecule non-RGD-mimetic inhibitors for RGD Integrins. J. Med. Chem. 60, 3241\u20133251 (2017).","journal-title":"J. Med. Chem."},{"key":"403_CR319","first-page":"288ra279","volume":"7","author":"NI Reed","year":"2015","unstructured":"Reed, N. I. et al. The \u03b1v\u03b21 integrin plays a critical in vivo role in tissue fibrosis. Sci. Transl Med. 7, 288ra279 (2015).","journal-title":"Sci. Transl Med."},{"key":"403_CR320","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1016\/S0618-8278(19)30103-3","volume":"70","author":"J Schaub","year":"2019","unstructured":"Schaub, J. et al. Targeted disruption of TGF-\u03b2 activation by an \u0391V\u03b21 integrin inhibitor significantly reduces liver fibrosis in CCl4 mice and human NASH liver slices. J. Hepatol. 70, e57\u2013e58 (2019).","journal-title":"J. Hepatol."},{"key":"403_CR321","doi-asserted-by":"publisher","DOI":"10.1101\/2020.05.14.084913","author":"E Dodagatta-Marri","year":"2020","unstructured":"Dodagatta-Marri, E. et al. Integrin av\u03b28 on T cells is responsible for suppression of anti-tumor immunity in syngeneic models and is a promising target for tumor immunotherapy. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2020.05.14.084913 (2020).","journal-title":"bioRxiv"},{"key":"403_CR322","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1126\/science.aau2909","volume":"362","author":"S Li\u00e9nart","year":"2018","unstructured":"Li\u00e9nart, S. et al. Structural basis of latent TGF-\u03b21 presentation and activation by GARP on human regulatory T cells. Science 362, 952\u2013956 (2018).","journal-title":"Science"},{"key":"403_CR323","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"403_CR324","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1200\/JCO.2017.75.1644","volume":"36","author":"FS Hodi","year":"2018","unstructured":"Hodi, F. S. et al. Immune-modified response evaluation criteria in solid tumors (imRECIST): Refining guidelines to assess the clinical benefit of cancer immunotherapy. J. Clin. Oncol. 36, 850\u2013858 (2018).","journal-title":"J. Clin. Oncol."},{"key":"403_CR325","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour, L. et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 18, e143\u2013e152 (2017).","journal-title":"Lancet Oncol."},{"key":"403_CR326","doi-asserted-by":"crossref","first-page":"5200","DOI":"10.1158\/0008-5472.CAN-04-0018","volume":"64","author":"G Subramanian","year":"2004","unstructured":"Subramanian, G. et al. Targeting endogenous transforming growth factor \u03b2 receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1. Cancer Res. 64, 5200\u20135211 (2004).","journal-title":"Cancer Res."},{"key":"403_CR327","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/nrd3810","volume":"11","author":"RJ Akhurst","year":"2012","unstructured":"Akhurst, R. J. & Hata, A. Targeting the TGF\u03b2 signalling pathway in disease. Nat. Rev. Drug Discov. 11, 790\u2013811 (2012).","journal-title":"Nat. Rev. Drug Discov."},{"key":"403_CR328","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1172\/JCI0215234","volume":"109","author":"RS Muraoka","year":"2002","unstructured":"Muraoka, R. S. et al. Blockade of TGF-\u03b2 inhibits mammary tumor cell viability, migration, and metastases. J. Clin. Invest. 109, 1551\u20131559 (2002).","journal-title":"J. Clin. Invest."},{"key":"403_CR329","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10637-014-0192-4","volume":"33","author":"J Rodon","year":"2015","unstructured":"Rodon, J. et al. Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-\u03b2 receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer. Invest. New Drugs 33, 357\u2013370 (2015).","journal-title":"Invest. New Drugs"},{"key":"403_CR330","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s00280-015-2895-4","volume":"76","author":"Y Fujiwara","year":"2015","unstructured":"Fujiwara, Y. et al. Phase 1 study of galunisertib, a TGF-\u03b2 receptor I kinase inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother. Pharmacol. 76, 1143\u20131152 (2015).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"403_CR331","first-page":"4479","volume":"9","author":"S Herbertz","year":"2015","unstructured":"Herbertz, S. et al. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-\u03b2 signaling pathway. Drug Des. Devel. Ther. 9, 4479\u20134499 (2015).","journal-title":"Drug Des. Devel. Ther."},{"key":"403_CR332","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.canlet.2013.12.018","volume":"346","author":"T Biswas","year":"2014","unstructured":"Biswas, T., Gu, X., Yang, J., Ellies, L. G. & Sun, L. Z. Attenuation of TGF-\u03b2 signaling supports tumor progression of a mesenchymal-like mammary tumor cell line in a syngeneic murine model. Cancer Lett. 346, 129\u2013138 (2014).","journal-title":"Cancer Lett."},{"key":"403_CR333","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1158\/1078-0432.CCR-19-2370","volume":"26","author":"Y Yang","year":"2020","unstructured":"Yang, Y. et al. The outcome of TGF\u03b2 antagonism in metastatic breast cancer models in vivo reflects a complex balance between tumor-suppressive and proprogression activities of TGF\u03b2. Clin. Cancer Res. 26, 643\u2013656 (2020).","journal-title":"Clin. Cancer Res."},{"key":"403_CR334","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/ncb2861","volume":"15","author":"P Bragado","year":"2013","unstructured":"Bragado, P. et al. TGF-\u03b22 dictates disseminated tumour cell fate in target organs through TGF-\u03b2-RIII and p38\u03b1\/\u03b2 signalling. Nat. Cell Biol. 15, 1351\u20131361 (2013).","journal-title":"Nat. Cell Biol."},{"key":"403_CR335","doi-asserted-by":"crossref","DOI":"10.1038\/srep36520","volume":"6","author":"K Yumoto","year":"2016","unstructured":"Yumoto, K. et al. Axl is required for TGF-\u03b22-induced dormancy of prostate cancer cells in the bone marrow. Sci. Rep. 6, 36520 (2016).","journal-title":"Sci. Rep."},{"key":"403_CR336","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.neo.2018.12.001","volume":"21","author":"J Jiang","year":"2019","unstructured":"Jiang, J. et al. PRRX1 regulates cellular phenotype plasticity and dormancy of head and neck squamous cell carcinoma through miR-642b-3p. Neoplasia 21, 216\u2013229 (2019).","journal-title":"Neoplasia"},{"key":"403_CR337","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/0008-5472.CAN-10-2941","volume":"71","author":"EC Connolly","year":"2011","unstructured":"Connolly, E. C. et al. Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long term T\u03b2RI\/II kinase inhibition with LY2109761. Cancer Res. 71, 1\u201311 (2011).","journal-title":"Cancer Res."},{"issue":"Suppl. 13","key":"403_CR338","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1158\/1538-7445.AM2019-2627","volume":"79","author":"D Ciardiello","year":"2019","unstructured":"Ciardiello, D. et al. Inhibition of TGF\u03b2 in colorectal cancer cells is associated with compensatory activation of AXL and p38 MAPK signaling pathways [abstract]. Cancer Res. 79 (Suppl. 13), 2627 (2019).","journal-title":"Cancer Res."},{"key":"403_CR339","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00262-015-1653-0","volume":"64","author":"ME Lacouture","year":"2015","unstructured":"Lacouture, M. E. et al. Cutaneous keratoacanthomas\/squamous cell carcinomas associated with neutralization of transforming growth factor \u03b2 by the monoclonal antibody fresolimumab (GC1008). Cancer Immunol. Immunother. 64, 437\u2013446 (2015).","journal-title":"Cancer Immunol. Immunother."},{"key":"403_CR340","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1158\/1078-0432.CCR-17-2653","volume":"24","author":"J Strauss","year":"2018","unstructured":"Strauss, J. et al. Phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF\u03b2, in advanced solid tumors. Clin. Cancer Res. 24, 1287\u20131295 (2018).","journal-title":"Clin. Cancer Res."},{"key":"403_CR341","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1177\/0192623311416259","volume":"39","author":"MJ Anderton","year":"2011","unstructured":"Anderton, M. J. et al. Induction of heart valve lesions by small-molecule ALK5 inhibitors. Toxicol. Pathol. 39, 916\u2013924 (2011).","journal-title":"Toxicol. Pathol."},{"key":"403_CR342","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s12012-014-9297-4","volume":"15","author":"RJ Kovacs","year":"2015","unstructured":"Kovacs, R. J. et al. Cardiac safety of TGF-\u03b2 receptor I kinase inhibitor LY2157299 monohydrate in cancer patients in a first-in-human dose study. Cardiovasc. Toxicol. 15, 309\u2013323 (2015).","journal-title":"Cardiovasc. Toxicol."},{"key":"403_CR343","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/toxsci\/kfaa024","volume":"175","author":"MS Mitra","year":"2020","unstructured":"Mitra, M. S. et al. A potent pan-TGF\u03b2 neutralizing monoclonal antibody elicits cardiovascular toxicity in mice and Cynomolgus monkeys. Toxicol. Sci. 175, 24\u201334 (2020).","journal-title":"Toxicol. Sci."},{"key":"403_CR344","first-page":"1077","volume":"10","author":"MH Barcellos-Hoff","year":"1996","unstructured":"Barcellos-Hoff, M. H. & Dix, T. A. Redox-mediated activation of latent transforming growth factor-\u03b21. Mol. Endocrinol. 10, 1077\u20131083 (1996).","journal-title":"Mol. Endocrinol."},{"key":"403_CR345","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/sj.onc.1201433","volume":"15","author":"M Martin","year":"1997","unstructured":"Martin, M. et al. Coactivation of AP-1 activity and TGF-\u03b21 gene expression in the stress response of normal skin cells to ionizing radiation. Oncogene 15, 981\u2013989 (1997).","journal-title":"Oncogene"},{"key":"403_CR346","first-page":"3880","volume":"53","author":"MH Barcellos-Hoff","year":"1993","unstructured":"Barcellos-Hoff, M. H. Radiation-induced transforming growth factor \u03b2 and subsequent extracellular matrix reorganization in murine mammary gland. Cancer Res. 53, 3880\u20133886 (1993).","journal-title":"Cancer Res."},{"key":"403_CR347","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1158\/0008-5472.CAN-14-3511","volume":"75","author":"C Vanpouille-Box","year":"2015","unstructured":"Vanpouille-Box, C. et al. TGF\u03b2 is a master regulator of radiation therapy-induced antitumor immunity. Cancer Res. 75, 2232\u20132242 (2015).","journal-title":"Cancer Res."},{"key":"403_CR348","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1158\/1078-0432.CCR-17-3322","volume":"24","author":"SC Formenti","year":"2018","unstructured":"Formenti, S. C. et al. Focal irradiation and systemic TGF\u03b2 blockade in metastatic breast Cancer. Clin. Cancer Res. 24, 2493\u20132504 (2018).","journal-title":"Clin. Cancer Res."},{"key":"403_CR349","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1172\/JCI65416","volume":"123","author":"NE Bhola","year":"2013","unstructured":"Bhola, N. E. et al. TGF-\u03b2 inhibition enhances chemotherapy action against triple-negative breast cancer. J. Clin. Invest. 123, 1348\u20131358 (2013).","journal-title":"J. Clin. Invest."},{"key":"403_CR350","doi-asserted-by":"crossref","first-page":"995","DOI":"10.3390\/ijms18050995","volume":"18","author":"D Capper","year":"2017","unstructured":"Capper, D. et al. Biomarker and histopathology evaluation of patients with recurrent glioblastoma treated with Galunisertib, Lomustine, or the combination of Galunisertib and Lomustine. Int. J. Mol. Sci. 18, 995 (2017).","journal-title":"Int. J. Mol. Sci."},{"key":"403_CR351","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1002\/mc.22592","volume":"56","author":"N Ungerleider","year":"2017","unstructured":"Ungerleider, N., Han, C., Zhang, J., Yao, L. & Wu, T. TGF\u03b2 signaling confers sorafenib resistance via induction of multiple RTKs in hepatocellular carcinoma cells. Mol. Carcinog. 56, 1302\u20131311 (2017).","journal-title":"Mol. Carcinog."},{"key":"403_CR352","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000056","volume":"10","author":"RK Kelley","year":"2019","unstructured":"Kelley, R. K. et al. A phase 2 study of Galunisertib (TGF-\u03b21 receptor type I inhibitor) and Sorafenib in patients with advanced hepatocellular carcinoma. Clin. Transl Gastroenterol. 10, e00056 (2019).","journal-title":"Clin. Transl Gastroenterol."},{"key":"403_CR353","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/s41416-018-0246-z","volume":"119","author":"D Melisi","year":"2018","unstructured":"Melisi, D. et al. Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. Br. J. Cancer 119, 1208\u20131214 (2018).","journal-title":"Br. J. Cancer"},{"key":"403_CR354","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s40425-018-0356-4","volume":"6","author":"RB Holmgaard","year":"2018","unstructured":"Holmgaard, R. B. et al. Targeting the TGF\u03b2 pathway with galunisertib, a TGF\u03b2RI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade. J. Immunother. Cancer 6, 47 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"403_CR355","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.cell.2019.10.029","volume":"179","author":"S Jiao","year":"2019","unstructured":"Jiao, S. et al. Differences in tumor microenvironment dictate T helper lineage polarization and response to immune checkpoint therapy. Cell 179, 1177\u20131190 (2019).","journal-title":"Cell"},{"key":"403_CR356","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1263412","volume":"6","author":"MZ Noman","year":"2017","unstructured":"Noman, M. Z. et al. The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200. Oncoimmunology 6, e1263412 (2017).","journal-title":"Oncoimmunology"},{"key":"403_CR357","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.canlet.2019.05.021","volume":"458","author":"A Lequeux","year":"2019","unstructured":"Lequeux, A. et al. Impact of hypoxic tumor microenvironment and tumor cell plasticity on the expression of immune checkpoints. Cancer Lett. 458, 13\u201320 (2019).","journal-title":"Cancer Lett."},{"key":"403_CR358","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","volume":"271","author":"DR Leach","year":"1996","unstructured":"Leach, D. R., Krummel, M. F. & Allison, J. P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734\u20131736 (1996).","journal-title":"Science"},{"key":"403_CR359","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1158\/1078-0432.CCR-18-0762","volume":"25","author":"A Sharma","year":"2019","unstructured":"Sharma, A. et al. Anti-CTLA-4 immunotherapy does not deplete FOXP3+ regulatory T Cells (Tregs) in human cancers. Clin. Cancer Res. 25, 1233\u20131238 (2019).","journal-title":"Clin. Cancer Res."},{"key":"403_CR360","doi-asserted-by":"crossref","first-page":"22699","DOI":"10.1073\/pnas.1821218116","volume":"116","author":"SC Wei","year":"2019","unstructured":"Wei, S. C. et al. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. Proc. Natl Acad. Sci. USA 116, 22699\u201322709 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"403_CR361","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin, J. et al. Five-year survival with combined Nivolumab and Ipilimumab in advanced melanoma. N. Engl. J. Med. 381, 1535\u20131546 (2019).","journal-title":"N. Engl. J. Med."},{"key":"403_CR362","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","volume":"165","author":"W Hugo","year":"2016","unstructured":"Hugo, W. et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165, 35\u201344 (2016).","journal-title":"Cell"},{"key":"403_CR363","doi-asserted-by":"crossref","first-page":"re10","DOI":"10.1126\/scisignal.aad0416","volume":"8","author":"RJ Akhurst","year":"2015","unstructured":"Akhurst, R. J. & Padgett, R. W. Matters of context guide future research in TGF\u03b2 superfamily signaling. Sci. Signal. 8, re10 (2015).","journal-title":"Sci. Signal."},{"key":"403_CR364","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.3892\/or.2017.5894","volume":"38","author":"S Funaki","year":"2017","unstructured":"Funaki, S. et al. Chemotherapy enhances programmed cell death 1\/ligand 1 expression via TGF-\u03b2 induced epithelial mesenchymal transition in non-small cell lung cancer. Oncol. Rep. 38, 2277\u20132284 (2017).","journal-title":"Oncol. Rep."},{"key":"403_CR365","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1158\/2159-8290.CD-15-1347","volume":"6","author":"BV Park","year":"2016","unstructured":"Park, B. V. et al. TGF\u03b21-mediated SMAD3 enhances PD-1 expression on antigen-specific T cells in cancer. Cancer Discov. 6, 1366\u20131381 (2016).","journal-title":"Cancer Discov."},{"key":"403_CR366","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000433","volume":"8","author":"H Lind","year":"2020","unstructured":"Lind, H. et al. Dual targeting of TGF-\u03b2 and PD-L1 via a bifunctional anti-PD-L1\/TGF-\u03b2RII agent: status of preclinical and clinical advances. J. Immunother. Cancer 8, e000433 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"403_CR367","doi-asserted-by":"crossref","first-page":"75217","DOI":"10.18632\/oncotarget.20680","volume":"8","author":"C Jochems","year":"2017","unstructured":"Jochems, C. et al. Analyses of functions of an anti-PD-L1\/TGF\u03b2R2 bispecific fusion protein (M7824). Oncotarget 8, 75217\u201375231 (2017).","journal-title":"Oncotarget"},{"key":"403_CR368","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1349589","volume":"6","author":"JM David","year":"2017","unstructured":"David, J. M. et al. A novel bifunctional anti-PD-L1\/TGF-\u03b2 trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells. Oncoimmunology 6, e1349589 (2017).","journal-title":"Oncoimmunology"},{"key":"403_CR369","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1016\/j.celrep.2018.05.050","volume":"23","author":"D Wang","year":"2018","unstructured":"Wang, D. et al. Targeting EZH2 reprograms intratumoral regulatory T cells to enhance cancer immunity. Cell Rep. 23, 3262\u20133274 (2018).","journal-title":"Cell Rep."},{"key":"403_CR370","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.4049\/jimmunol.1003099","volume":"186","author":"SA McClymont","year":"2011","unstructured":"McClymont, S. A. et al. Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J. Immunol. 186, 3918\u20133926 (2011).","journal-title":"J. Immunol."},{"key":"403_CR371","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/cgt.2009.15","volume":"16","author":"J Nemunaitis","year":"2009","unstructured":"Nemunaitis, J. et al. Phase II trial of Belagenpumatucel-L, a TGF-\u03b22 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients. Cancer Gene Ther. 16, 620\u2013624 (2009).","journal-title":"Cancer Gene Ther."},{"key":"403_CR372","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1016\/j.ejca.2015.07.035","volume":"51","author":"G Giaccone","year":"2015","unstructured":"Giaccone, G. et al. A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. Eur. J. Cancer 51, 2321\u20132329 (2015).","journal-title":"Eur. J. Cancer"},{"key":"403_CR373","doi-asserted-by":"crossref","first-page":"10247","DOI":"10.1158\/0008-5472.CAN-08-1494","volume":"68","author":"S Kim","year":"2008","unstructured":"Kim, S. et al. Systemic blockade of transforming growth factor-\u03b2 signaling augments the efficacy of immunogene therapy. Cancer Res. 68, 10247\u201310256 (2008).","journal-title":"Cancer Res."},{"key":"403_CR374","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0022-1759(86)90015-3","volume":"88","author":"LM Muul","year":"1986","unstructured":"Muul, L. M., Director, E. P., Hyatt, C. L. & Rosenberg, S. A. Large scale production of human lymphokine activated killer cells for use in adoptive immunotherapy. J. Immunol. Methods 88, 265\u2013275 (1986).","journal-title":"J. Immunol. Methods"},{"key":"403_CR375","doi-asserted-by":"crossref","first-page":"3966","DOI":"10.1158\/1078-0432.CCR-08-0356","volume":"14","author":"A Wallace","year":"2008","unstructured":"Wallace, A. et al. Transforming growth factor-\u03b2 receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers. Clin. Cancer Res. 14, 3966\u20133974 (2008).","journal-title":"Clin. Cancer Res."},{"key":"403_CR376","first-page":"43","volume":"18","author":"P Hwu","year":"1994","unstructured":"Hwu, P. & Rosenberg, S. A. The genetic modification of T cells for cancer therapy: an overview of laboratory and clinical trials. Cancer Detect. Prev. 18, 43\u201350 (1994).","journal-title":"Cancer Detect. Prev."},{"key":"403_CR377","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp, S. A. et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509\u20131518 (2013).","journal-title":"N. Engl. J. Med."},{"key":"403_CR378","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/CJI.0b013e318177092b","volume":"31","author":"AE Foster","year":"2008","unstructured":"Foster, A. E. et al. Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-\u03b2 receptor. J. Immunother. 31, 500\u2013505 (2008).","journal-title":"J. Immunother."},{"key":"403_CR379","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nchembio.2565","volume":"14","author":"ZL Chang","year":"2018","unstructured":"Chang, Z. L. et al. Rewiring T-cell responses to soluble factors with chimeric antigen receptors. Nat. Chem. Biol. 14, 317\u2013324 (2018).","journal-title":"Nat. Chem. Biol."},{"key":"403_CR380","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/btm2.10097","volume":"3","author":"AJ Hou","year":"2018","unstructured":"Hou, A. J., Chang, Z. L., Lorenzini, M. H., Zah, E. & Chen, Y. Y. TGF-\u03b2-responsive CAR-T cells promote anti-tumor immune function. Bioeng. Transl Med. 3, 75\u201386 (2018).","journal-title":"Bioeng. Transl Med."},{"key":"403_CR381","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.cell.2012.10.035","volume":"151","author":"S Huang","year":"2012","unstructured":"Huang, S. et al. MED12 controls the response to multiple cancer drugs through regulation of TGF-\u03b2 receptor signaling. Cell 151, 937\u2013950 (2012).","journal-title":"Cell"},{"key":"403_CR382","doi-asserted-by":"crossref","first-page":"5645","DOI":"10.1007\/s11033-019-04958-6","volume":"46","author":"M Panda","year":"2019","unstructured":"Panda, M. & Biswal, B. K. Cell signaling and cancer: a mechanistic insight into drug resistance. Mol. Biol. Rep. 46, 5645\u20135659 (2019).","journal-title":"Mol. Biol. Rep."},{"key":"403_CR383","doi-asserted-by":"crossref","first-page":"djw261","DOI":"10.1093\/jnci\/djw261","volume":"109","author":"JL Gulley","year":"2017","unstructured":"Gulley, J. L. et al. Role of antigen spread and distinctive characteristics of immunotherapy in cancer treatment. J. Natl Cancer Inst. 109, djw261 (2017).","journal-title":"J. Natl Cancer Inst."},{"key":"403_CR384","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1158\/1078-0432.CCR-19-1457","volume":"26","author":"KA Autio","year":"2020","unstructured":"Autio, K. A., Boni, V., Humphrey, R. W. & Naing, A. Probody therapeutics: an emerging class of therapies designed to enhance on-target effects with reduced off-tumor toxicity for use in immuno-oncology. Clin. Cancer Res. 26, 984\u2013989 (2020).","journal-title":"Clin. Cancer Res."},{"key":"403_CR385","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s00262-017-2025-8","volume":"66","author":"O Hamid","year":"2017","unstructured":"Hamid, O., Hoffner, B., Gasal, E., Hong, J. & Carvajal, R. D. Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer. Cancer Immunol. Immunother. 66, 1249\u20131264 (2017).","journal-title":"Cancer Immunol. Immunother."},{"key":"403_CR386","doi-asserted-by":"crossref","first-page":"7173","DOI":"10.1074\/jbc.M116.768754","volume":"292","author":"SK Kim","year":"2017","unstructured":"Kim, S. K. et al. An engineered transforming growth factor \u03b2 (TGF-\u03b2) monomer that functions as a dominant negative to block TGF-\u03b2 signaling. J. Biol. Chem. 292, 7173\u20137188 (2017).","journal-title":"J. Biol. Chem."},{"key":"403_CR387","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/antib8010013","volume":"8","author":"T Chanier","year":"2019","unstructured":"Chanier, T. & Chames, P. Nanobody engineering: toward next generation immunotherapies and immunoimaging of cancer. Antibodies 8, 13 (2019).","journal-title":"Antibodies"},{"key":"403_CR388","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ccell.2017.07.007","volume":"32","author":"Cancer Genome Atlas Research Network","year":"2017","unstructured":"Cancer Genome Atlas Research Network. Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell 32, 185\u2013203 (2017).","journal-title":"Cancer Cell"},{"key":"403_CR389","doi-asserted-by":"crossref","first-page":"44418","DOI":"10.18632\/oncotarget.17901","volume":"8","author":"A Lechner","year":"2017","unstructured":"Lechner, A. et al. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma. Oncotarget 8, 44418\u201344433 (2017).","journal-title":"Oncotarget"},{"key":"403_CR390","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1158\/2326-6066.CIR-15-0024","volume":"3","author":"EM Van Allen","year":"2015","unstructured":"Van Allen, E. M. et al. Long-term benefit of PD-L1 blockade in lung cancer associated with JAK3 activation. Cancer Immunol. Res. 3, 855\u2013863 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"403_CR391","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1158\/1078-0432.CCR-18-3041","volume":"25","author":"MP Trefny","year":"2019","unstructured":"Trefny, M. P. et al. A variant of a killer cell immunoglobulin-like receptor is associated with resistance to PD-1 blockade in lung cancer. Clin. Cancer Res. 25, 3026\u20133034 (2019).","journal-title":"Clin. Cancer Res."},{"key":"403_CR392","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.1159397","volume":"321","author":"L Valle","year":"2008","unstructured":"Valle, L. et al. Germline allele-specific expression of TGFBR1 confers an increased risk of colorectal cancer. Science 321, 1361\u20131365 (2008).","journal-title":"Science"},{"key":"403_CR393","doi-asserted-by":"crossref","first-page":"7723","DOI":"10.1073\/pnas.1318761111","volume":"111","author":"K Kawasaki","year":"2014","unstructured":"Kawasaki, K. et al. Genetic variants of Adam17 differentially regulate TGF\u03b2 signaling to modify vascular pathology in mice and humans. Proc. Natl Acad. Sci. USA 111, 7723\u20137728 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"403_CR394","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy, B. et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359, 91\u201397 (2018).","journal-title":"Science"},{"key":"403_CR395","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.jtho.2019.04.007","volume":"14","author":"Y Jin","year":"2019","unstructured":"Jin, Y. et al. The diversity of gut microbiome is associated with favorable responses to anti-programmed death 1 immunotherapy in Chinese patients with NSCLC. J. Thorac. Oncol. 14, 1378\u20131389 (2019).","journal-title":"J. Thorac. Oncol."},{"key":"403_CR396","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10391","volume":"7","author":"K Dubin","year":"2016","unstructured":"Dubin, K. et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat. Commun. 7, 10391 (2016).","journal-title":"Nat. Commun."},{"key":"403_CR397","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1200\/JCO.2004.99.271","volume":"22","author":"B Pasche","year":"2004","unstructured":"Pasche, B. et al. TGFBR1*6A and cancer: a meta-analysis of 12 case-control studies. J. Clin. Oncol. 22, 756\u2013758 (2004).","journal-title":"J. Clin. Oncol."},{"key":"403_CR398","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/MAJ.0b013e3181cef1a1","volume":"339","author":"M Izad","year":"2010","unstructured":"Izad, M. et al. Cytokines genes polymorphisms and risk of multiple sclerosis. Am. J. Med. Sci. 339, 327\u2013331 (2010).","journal-title":"Am. J. Med. Sci."},{"key":"403_CR399","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/ng0297-207","volume":"15","author":"M Bonyadi","year":"1997","unstructured":"Bonyadi, M. et al. Mapping of a major genetic modifier of embryonic lethality in TGF \u03b21 knockout mice. Nat. Genet. 15, 207\u2013211 (1997).","journal-title":"Nat. Genet."},{"key":"403_CR400","volume":"3","author":"M Benzinou","year":"2012","unstructured":"Benzinou, M. et al. Mouse and human strategies identify PTPN14 as a modifier of angiogenesis and hereditary haemorrhagic telangiectasia. Nat. Commun. 3, 616 (2012).","journal-title":"Nat. Commun."},{"key":"403_CR401","doi-asserted-by":"crossref","first-page":"18042","DOI":"10.1073\/pnas.1205374109","volume":"109","author":"J Freimuth","year":"2012","unstructured":"Freimuth, J. et al. Epistatic interactions between Tgfb1 and genetic loci, Tgfbm2 and Tgfbm3, determine susceptibility to an asthmatic stimulus. Proc. Natl Acad. Sci. USA 109, 18042\u201318047 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"403_CR402","first-page":"6362","volume":"62","author":"SJ Engle","year":"2002","unstructured":"Engle, S. J. et al. Elimination of colon cancer in germ-free transforming growth factor \u03b21-deficient mice. Cancer Res. 62, 6362\u20136366 (2002).","journal-title":"Cancer Res."},{"key":"403_CR403","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan, V. et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359, 97\u2013103 (2018).","journal-title":"Science"},{"key":"403_CR404","doi-asserted-by":"crossref","DOI":"10.4161\/onci.26218","volume":"2","author":"JP Stevenson","year":"2013","unstructured":"Stevenson, J. P. et al. Immunological effects of the TGF\u03b2-blocking antibody GC1008 in malignant pleural mesothelioma patients. Oncoimmunology 2, e26218 (2013).","journal-title":"Oncoimmunology"},{"key":"403_CR405","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s40425-019-0633-x","volume":"7","author":"SC Formenti","year":"2019","unstructured":"Formenti, S. C. et al. Baseline T cell dysfunction by single cell network profiling in metastatic breast cancer patients. J. Immunother. Cancer 7, 177 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"403_CR406","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s00280-019-03807-4","volume":"83","author":"D Melisi","year":"2019","unstructured":"Melisi, D. et al. TGF\u03b2 receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer. Cancer Chemother. Pharmacol. 83, 975\u2013991 (2019).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"403_CR407","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s00280-019-03931-1","volume":"84","author":"I Gueorguieva","year":"2019","unstructured":"Gueorguieva, I. et al. Population pharmacokinetics and exposure-overall survival analysis of the transforming growth factor-\u03b2 inhibitor galunisertib in patients with pancreatic cancer. Cancer Chemother. Pharmacol. 84, 1003\u20131015 (2019).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"403_CR408","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1158\/1078-0432.CCR-14-1380","volume":"21","author":"J Rodon","year":"2015","unstructured":"Rodon, J. et al. First-in-human dose study of the novel transforming growth factor-\u03b2 receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma. Clin. Cancer Res. 21, 553\u2013560 (2015).","journal-title":"Clin. Cancer Res."},{"key":"403_CR409","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s10637-018-0636-3","volume":"37","author":"M Ikeda","year":"2019","unstructured":"Ikeda, M. et al. A phase 1b study of transforming growth factor-\u03b2 receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma. Invest. New Drugs 37, 118\u2013126 (2019).","journal-title":"Invest. New Drugs"},{"key":"403_CR410","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s00280-017-3313-x","volume":"79","author":"M Ikeda","year":"2017","unstructured":"Ikeda, M. et al. Phase 1b study of galunisertib in combination with gemcitabine in Japanese patients with metastatic or locally advanced pancreatic cancer. Cancer Chemother. Pharmacol. 79, 1169\u20131177 (2017).","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"Suppl. 13","key":"403_CR411","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1158\/1538-7445.AM2017-955","volume":"77","author":"H Pei","year":"2017","unstructured":"Pei, H. et al. LY3200882, a novel, highly selective TGF\u03b2RI small molecule inhibitor [abstract]. Cancer Res. 77 (Suppl. 13), 955 (2017).","journal-title":"Cancer Res."},{"key":"403_CR412","doi-asserted-by":"publisher","unstructured":"Yap, T. et al. AVID200, first-in-class TGF-b1 and -b3 selective inhibitor: results of a phase 1 monotherapy dose escalation study in solid tumors and evidence of targeted engagement in patients. J. Immunother. Cancer 8, https:\/\/doi.org\/10.1136\/LBA2019.10 (2020).","DOI":"10.1136\/LBA2019.10"},{"key":"403_CR413","doi-asserted-by":"crossref","first-page":"6976","DOI":"10.1158\/1078-0432.CCR-19-1338","volume":"25","author":"V Santini","year":"2019","unstructured":"Santini, V. et al. Phase II study of the ALK5 inhibitor Galunisertib in very low-, low-, and intermediate-risk myelodysplastic syndromes. Clin. Cancer Res. 25, 6976\u20136985 (2019).","journal-title":"Clin. Cancer Res."},{"key":"403_CR414","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1200\/JCO.2018.36.15_suppl.3031","volume":"36","author":"VL Keedy","year":"2018","unstructured":"Keedy, V. L. et al. Association of TGF-\u03b2 responsive signature with anti-tumor effect of vactosertib, a potent, oral TGF-\u03b2 receptor type I (TGFBRI) inhibitor in patients with advanced solid tumors. J. Clin. Oncol. 36, 3031\u20133031 (2018).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-020-0403-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-020-0403-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-020-0403-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T15:25:51Z","timestamp":1696433151000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-020-0403-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,24]]},"references-count":414,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["403"],"URL":"https:\/\/doi.org\/10.1038\/s41571-020-0403-1","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,24]]},"assertion":[{"value":"7 June 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.D. is a co-founder of Pliant Therapeutics. S.J.T. is an employee of Genentech. R.J.A. has sponsored research agreements with Pfizer and Bristol\u2013Myers Squibb and is a co-inventor of a patent on the use of anti-TGF\u03b2 antibodies that is co-owned by the University of California at San Francisco and XOMA.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}